1

CURRICULUM VITAE NAME: Howard Stephen Cuckle DATE OF BIRTH: 2nd January 1947 in Hull, England CONTACT: Yehuda HaHasid 3, Neve Tzedek 6515150, Israel (phone +972 54 209 1502); 43 Woodstock Close, Oxford, OX2 8DB, UK (phone +44 7946 873342); email h.s.cuckle@leeds.ac.uk UNIVERSITY EDUCATION: 1968-72 Leeds; 1972-76 Oxford, Balliol College and Wolfson College (Graduate Scholar) DEGREES: BA (Class 1) Mathematics & Philosophy, Leeds, 1972; MSc Applied Statistics, Oxford, 1976; DPhil Mathematical Logic, Oxford, 1975 THESES: Models for intuitionistic logic, Oxford, 1975; Maternal serum AFP in pregnancy, Oxford, 1976 PRESENT APPOINTMENTS: Visiting Associate Professor, Obstetrics and Gynecology, Faculty of Medicine, Tel Aviv University, Israel; 2013-. Adjunct Professor of Obstetrics and Gynecology, Columbia University Medical Center, New York, USA; 2006- Emeritus Professor, University of Leeds, UK; 2006- OTHER RESPONSIBILITIES: Chinese University Hong Kong, Centre for Research into Circulating Fetal Nucleic Acids, Scientific Advisory

Board Genome Ltd, Director Genome Screening Ltd, Director International Prenatal Screening Group, Scientific Committee International Society for Prenatal Diagnosis, Federation Co-Chair Journal of Fetal Medicine, International Advisory Board Journal of Medical Screening, Editorial Committee NHS Central Research and Development Committee, Standing Group on Health Technology, College of Experts Paediatric & Perinatal Epidemiology, Advisory Board Perinatal Quality Foundation, formally Nuchal Translucency Education and Quality Review program Prenatal Diagnosis, Editorial Board

PREVIOUS EMPLOYMENT: Trainee Manager, 1965-68 Mathematics Teacher, 1973-75 Cancer Studies Unit, Nuffield Department of Clinical Medicine, University of Oxford, Lecturer, 1975-82 Department of Social & Preventive Medicine, Tel Aviv University Medical School, Associate Professor, 1981-82 Oxford Region Cancer Screening Project, Deputy Director, 1982-83 Department of Environmental and Preventive Medicine, St Bartholomew's Hospital Medical College, Acting

Senior Lecturer, 1983-84, Senior Lecturer, 1984-90, Reader, 1990-91 Cancer Research Campaign, Fellow and Co-Director, Cancer Screening Research Group, 1989-91 West Berkshire DHA Breast Cancer Screening Programme, Manager, 1989-91 Reading Screening Centre, Deputy Director, 1983-91 Professor of Reproductive Epidemiology, University of Leeds, 1991-2006 Consultant in Epidemiology, Leeds Teaching Hospitals NHS Trust, 1991-2006

2

PREVIOUS NATIONAL AND INTERNATIONAL COMMITTEES: British Journal of Family Planning, Editorial Advisory Board (Statistical Adviser), 1993-99 Collaborative AChE Study Steering Committee, 1980-89 Department of Health, National Screening Committee, Down’s Syndrome Screening Programme. Software Group;

Laboratory Standards Working Group International Down’s Syndrome Screening Group, Chairman 1991-2009 Medical Research Council. Working Party on Urological Cancer, 1978-1982; Working Party on Leukaemia in

Adults, 1979-86. Working Party on Chronic Granulocytic Leukaemia, 1979-86; Working Party on Antiepileptic Drug Withdrawal Study, 1984-92; Working Party on Early Epilepsy & Single Seizures, Data Monitoring Committee (Chairman), 1993-2002; Trial of Breast Screening in Younger Women, Steering Committee and Management Group (Chairman), 1993-2011

NHS Breast Screening Programme, Information & Evaluation Group, 1989-91 NHS Central Research and Development Committee, Standing Group on Health Technology, Member of

Population Screening Panel, 1999-2000 NHS Central Research and Development Committee, Standing Group on Health Technology, Diagnostic

Technologies and Population Screening Panel Member, 2000-02 Paediatric & Perinatal Epidemiology, Member of Editorial Board, 1994-97 Royal College of Obstetrics and Gynaecology. Working Party on the Routine use of Ultrasound for Screening in

Obstetrics, 1995-97; Study Group on Screening for Down's Syndrome in the First Trimester 1996; Study Group on Problems of Early Pregnancy 1997; Study Group on Gene Identification, Manipulation and Therapy 1997

Special Non-invasive Advances in Foetal and Neonatal Evaluation Network, Advisory Board 2000-07; Special Allocation Fund (Chairman) 2000-07

UK Collaborative AFP Study Steering Committee, 1975-80 UK Co-ordinating Committee on Cancer Research. Breast Screening Research Sub-committee, 1988-93;

Screening Research Sub-committee, 1993-96 UK Trials in the Early Detection of Breast Cancer, Data Analysis Sub-group, 1985-90 US National Committee for Clinical Laboratory Standards. AFP Sub-committee, 1979-80

PREVIOUS HEALTH AUTHORITY COMMITTEES: City and Hackney DHA. Cervical Screening Steering Group (Chairman), 1986-91 Leeds Teaching Hospitals NHS Trust. Antenatal and Newborn Screening Unit Project Board, 2002-03 North East Thames RHA. Advisory Sub-Committee on Clinical Genetics, 1985-91; AFP Screening Group,

1987-91; Breast Screening Research Group, 1988-90 Oxford RHA. Breast Screening Group, 1988-89; Cancer Screening Project Working Group, 1982-87; Breast

Screening Research Group (Chairman), 1988-91; Breast Screening Programme Managers Group, 1989-91; Breast Screening Quality Assessment Group, 1989-91

West Berkshire HA Breast Screening Group, 1987-91 Yorkshire RHA Working Group on Health Gains for Antenatal Screening, 1992

PROFESSIONAL GROUPS: British Society for Human Genetics Clinical Genetics Society International Society for Prenatal Diagnosis International Society of Ultrasound in Obstetrics and Gynaecology Medical Screening Society Society for Social Medicine

CONSULTANT OR ADVISER: Amersham International Ltd, UK Ariosa Diagnostics Inc, USA British Breast Group DiaDexus Inc, USA GenesIT Software Ltd, Israel Genome Screening Ltd, UK

3

Israel Ministry of Health, Committee on Carcinogens, Mutagens and Teratogens Israel Ministry of Health, Committee on Antenatal Diagnosis MRC Multiple Sclerosis Co-ordinating Group Muscular Dystrophy Group of Great Britain Natera Diagnostics Inc, USA Netherlands Health Council, Committee on Prenatal Screening PerkinElmer Inc, USA ProMyco Diagnostics Ltd, Israel Sheba Medical Centre, Tel Hashomer, Israel USA National Committee for Clinical Laboratory Standards Wallac Oy, Finland

SCIENTIFIC REFEREEING: Acta Obstetricia et Gynecologica Scandinavica Action Research American Journal of Obstetrics & Gynecology American Journal of Public Health Annals of Clinical Biochemistry Biomed Central Brighton and Sussex University Hospitals British Journal of Cancer British Journal of Haematology British Journal of Obstetrics & Gynaecology British Journal of Family Planning British Medical Journal Cancer Research Campaign Clinical Chemistry Clinical Chemistry and Laboratory Medicine Clinical Genetics Cochrane Pregnancy and Child Group Department of Health Effective Health Care Bulletin European Journal of Obstetrics & Gynecology and Reproductive Biology European Journal of Human Genetics Expert Review of Molecular Diagnostics Fetal Diagnosis & Therapy Fertility & Sterility Genetics in Medicine Health Research Council of New Zealand Health Services Research Committee of Hong Kong Human Mutation Human Reproduction International Journal of Cancer International Journal of Epidemiology Israel Science Foundation Journal of Endocrinology Journal of Epidemiology & Community Health Journal of Investigative Medicine Journal of Medical Genetics Journal of Medical Screening Journal of Public Health Medicine Lancet New England Journal of Medicine Medical Research Council Human Mutation

4

National Institute for Clinical Excellence NHS R&D Programme in Health Technology Assessment Obstetrics & Gynecology Obstetrician & Gynaecologist Paediatric & Perinatal Epidemiology Prenatal Diagnosis Radiography Reproductive Biology Scottish Office, Department of Health Statistics in Medicine Teratology Thorax Tommy's Campaign Trent Health Authority Ultrasound in Obstetrics & Gynaecology Wellbeing

MEDICAL TEACHING: European School of Oncology Royal London Hospital Medical College St Bartholomew's Hospital Medical College Tel-Aviv University (Course Director in Social and Preventive Medicine) University of Cambridge University of Leeds University of Oxford Yorkshire Postgraduate Deanery

RESEARCH GRANTING BODIES: Action Research for the Crippled Child Cancer Research Campaign Department of Health East Riding Health Authority LGI Special Trustees Medical Research Council NHS R&D Programme North East Thames Regional Health Authority Oxford Regional Health Authority UK Co-ordinating Committee on Cancer Research Wellcome Trust Yorkshire Regional Health Authority

PATENTS: International Patent number PCT/GB88/00557 on “The use of oestriol, progesterone, 16-hydroxy-DHEAS and

DHEAS in screening for Down's syndrome”. US Patent number 6,025,149 on “Urinary screening for Down's syndrome and other aneuploides”. US Patent number 5,716,853 on “Prenatal Down's syndrome screening with assays specific for UGP”. International Patent number PCT/US94/00644 on “The isolation of fetal erythrocytes”. US Patent number 11,850,314 on “Testing process - method of determining an inclusive residual risk”. International Patent number PCT/US2009/032062 on “Methods for determining the risk of prenatal complications” US Patent number 61,306,747 on “Systems and methods for assessing risk of chromosomal disorders” EDITED BOOKS: Screening for Down's syndrome. (Eds. JG Grudzinskas, T Chard, M Chapman, H Cuckle). Cambridge University

Press, UK 1994 Down Syndrome Screening Policy and Economic Evaluations (Eds T Beazoglou, P Benn, H Cuckle, J Haddow,

5

J Kyriopoulos). Exandas, Athens 1999 Early prenatal diagnosis, fetal cells and DNA in the mother: Proceedings of the 12th Fetal Cell Workshop. (Eds. M

Macek, D Bianchi, H Cuckle). Charles University Press, Prague 2002. EDITED SPECIAL ISSUE JOURNALS: Seminars in Neonatology. Eds. H Cuckle, J Thornton. Elsevier, Orlando 1998. Am J Med Genet C Semin Med Genet. Prenatal and Fetal Diagnosis. Eds. S Gross, H Cuckle. Wiley-Liss, USA

2007. PUBLICATIONS: 1 Cuckle H. Models for intuitionistic logic. University of Oxford, 1975. (Doctoral Thesis). 2 Cuckle H. Maternal serum AFP in pregnancy. University of Oxford 1976. (Masters Thesis). 3 Wald NJ, Cuckle H. Routine testing for alpha-fetoprotein in amniotic fluid. Lancet 1976;i:1292-1293. 4 Wald NJ, Barker S, Cuckle H, Brock DJH, Stirrat G. Maternal serum AFP and spontaneous abortion. Brit J

Obstet Gynaecol 1977;84:357-362. 5 Brock DJH, Wald NJ, Cuckle H. Organisation of maternal serum alphafetoprotein screening for fetal

neural-tube defects. Lancet 1977;i:700. 6 Wald NJ, Cuckle H. Maternal serum alpha-fetoprotein measurement in antenatal screening for anencephaly and

spina bifida in early pregnancy. Report of the U.K. Collaborative Study on Alpha-Fetoprotein in Relation to Neural-Tube Defects. Lancet 1977;i:1323-1332.

7 Screening for neural tube defects. (unsigned leading article written jointly with Dr DJH Brock, Dr NJ Wald and Dr FP Woodford). Lancet 1977;i:1345-1346.

8 Wald N, Cuckle H, Stirrat GM, Bennett MJ, Turnbull AC. Maternal serum alpha-fetoprotein and low birth-weight. Lancet 1977;ii:268-270.

9 Wald N, Cuckle H, Stirrat G. Maternal serum alpha- fetoprotein levels in triplet and quadruplet pregnancy. Br J Obstet Gynaecol 1978;85:124-126.

10 Wald N, Cuckle H, Polani PE. Alpha-fetoprotein in antenatal diagnosis of neural-tube defects. Br Med J 1978;1:238.

11 Wald N, Cuckle H, Stirrat G. Screening for neural-tube defects Lancet 1978;i:495. 12 Wald NJ, Cuckle HS, Brock DJH, Polani PE. Screening for neural-tube defects. Lancet 1978;ii:216-217. 13 Wald NJ, Cuckle HS, Stirrat GM, Turnbull AC. Maternal serum alpha-fetoprotein and birth weight in twin

pregnancies. Br J Obstet Gynaecol 1978;85:582-584. 14 Wald N, Barker S, Cuckle H, Brock D, Stirrat G. Fetal loss after amniocentesis. Lancet 1978;ii:1093. 15 Wald N, Barker S, Cuckle H, Brock D, Stirrat G. Amniocentesis and the alpha-fetoprotein screening

programme. Lancet 1979;i:40. 16 Wald N, Cuckle H. Antenatal screening for neural-tube defects. In: Alpha-Fetoprotein in Clinical Medicine

(Eds HK Weitzel, J Schneider), Georg Thieme, Stuttgart, 29-33, 1979. 17 Wald NJ, Cuckle HS, Boreham J, Stirrat GM, Turnbull AC. Maternal serum alpha-fetoprotein and diabetes

mellitus. Br J Obstet Gynaecol 1979;86:101-105. 18 Wald NJ, Cuckle HS, Boreham J, Brett R, Stirrat GM, Bennett MJ, Turnbull AC, Solymar M, Jones N, Bobrow

M, Evans CJ. Antenatal screening in Oxford for fetal neural-tube defects. Br J Obstet Gynaecol 1979;86:91-100.

19 Wald NJ, Cuckle HS, Peck S, Stirrat GM, Turnbull AC. Maternal serum alpha-fetoprotein in relation to zygosity. Br Med J 1979;1:455-457.

20 Stirrat GM, Turnbull AC, Bennett MJ, Bobrow M, Lindenbaum RH, Wald NJ, Cuckle HS. Clinical dilemmas arising from the antenatal diagnosis of neural tube defects. Br J Obstet Gynaecol 1979;86:161-166.

21 Smith AD, Wald NJ, Cuckle HS, Stirrat G, Bobrow M, Lagercrantz H. Amniotic fluid acetylcholinesterase as a possible diagnostic test for neural-tube defects in early pregnancy. Lancet 1979;i:685-688.

22 Bennett MJ, Solymar M, Turnbull AC, Cuckle HS, Wald NJ. Pregnancies associated with low maternal serum alpha-fetoprotein concentrations. Am J Obstet Gynecol 1979;135:545-546.

23 Cuckle H. Should a national screening programme for spina bifida be introduced. Mims Magazine 1979;1:5-6. 24 Cuckle H, Galton DAG, Peto R. Chemotherapy of acute myeloid leukaemia in adults. Report of the MRCs

sixth trial (chemotherapy). Br J Cancer 1979;39:69-86. 25 Wald N, Cuckle H, Harwood C. Screening for open neural-tube defects in England and Wales. Br Med J

1979;2:331.

6

26 Wald N, Cuckle H. Amniotic fluid alpha-fetoprotein measurement in the antenatal diagnosis of anencephaly and open spina bifida in early pregnancy. Second Report of the U.K. Collaborative AFP Study. Lancet 1979;ii:651-662.

27 Wald N, Cuckle H, Boreham J, Stirrat G. Small biparietal diameter of fetuses with spina bifida: Implications for antenatal diagnosis. Br J Obstet Gynaecol 1980; 87:219-221.

28 Wald N, Cuckle H. The quality control of alpha-fetoprotein reagents and assay for the antenatal screening and diagnosis of open neural-tube defects. Clin. Chim. Acta 1980;105:9-24.

29 Wald N, Cuckle H, Boreham J, Althouse R. Birthweight of infants with spina bifida cystica. Br J Obstet Gynaecol 1980;87:578-581.

30 Cuckle H, Galton DAG, Peto R, Paul E, Gilham M. Report of the MRC second myelomatosis trial after five completed years of follow-up. Br J Cancer 1980;42:813-822.

31 Wald NJ, Cuckle HS. Alpha-fetoprotein in the antenatal diagnosis of open neural-tube defects. Br J Hosp Med 1980;23:473-489.

32 Wald NJ, Cuckle HS. Relation between maternal serum and amniotic fluid AFP. Lancet 1980;i:257. 33 Wald NJ, Cuckle HS. Cut-off levels in AFP screening. Lancet 1980;i:542. 34 Cuckle H, Wald N, Brock D. Screening for neural-tube defects. Lancet 1980;i:600. 35 Stirrat GM, Gough JD, Bullock S, Wald N, Cuckle H. Raised maternal serum AFP, oligohydramnios and poor

fetal outcome. Br J Obstet Gynaecol 1981;88:231-235. 36 Wald NJ, Cuckle HS, Catz C, Dayton D, Reimer C. AFP screening and dignosis of fetal open neural-tube

defects: the need for quality control. Am J Obstet Gynecol 1981; 141:1-4. 37 Cuckle H, Wald N, Brock D. Screening for neural-tube defects. Lancet 1980;i:1090. 38 Wald N, Cuckle H, Boreham J, Turnbull A. Maternal serum AFP and birth weight. Br J Obstet Gynaecol

1980; 87:860-863. 39 Wald N, Cuckle H, Barlow R, Smith D, Stirrat G, Turnbull A, Bobrow M, Brock D, Stein S. Early antenatal

diagnosis of exomphalos. Lancet 1980;i:1368-1369. 40 Wald NJ, Cuckle HS, Haddow JE. Should ultrasound be used to estimate gestational age in the screening and

antenatal diagnosis of open neural tube defects? Lancet 1980; ii:690. 41 Cuckle H, Doll R, Morgan LG. Mortality study of men working with soluble nickel compounds. In: Nickel

Toxicology. (Eds SS Brown, FW Sunderman), Academic Press, London, 11-22, 1981. 42 Wald NJ, Cuckle HS. Antenatal detection of neural tube defects. Med Laboratory 1982;10:13-26. 43 Wald N, Cuckle H, Boreham J, Terzian E, Redman C. The effect of maternal weight on maternal serum

alpha-fetoprotein levels. Br J Obstet Gynaecol 1981; 88:1094-1096. 44 Cuckle HS, Wald NJ. Amniotic fluid acetylcholinesterase. Lancet 1981;i:95-96. 45 Wald NJ, Cuckle HS. Raised maternal serum alpha-fetoprotein levels in subsequent pregnancies. Lancet

1981;i:1103. 46 Arthrogryposis multiplex congenita. (unsigned leading article). Br Med J 1981;3:2-3. 47 Wald N, Cuckle H, Stirrat G, Lorber J. Maternal alpha-fetoprotein screening. Br Med J 1981;283:1054. 48 Wald NJ, Cuckle HS. Amniotic fluid acetylcholinesterase eletrophoresis as a secondary test in the diagnosis of

anencephaly and open spina bifida in early pregnancy. Report of the Collaborative Acetylcholinesterase Study. Lancet 1981;ii:321-324.

49 Wald NJ, Cuckle HS, Boreham J, Stirrat GM, Turnbull AC. Maternal serum alpha-fetoprotein and diabetes mellitus. Br J Obstet Gynaecol 1981;88:1068-1069.

50 Wald NJ, Cuckle HS, Boreham J. Maternal serum a-fetoprotein and low birth weight in relation to gestational age. Br J Obstet Gynaecol 1982;89:216-217.

51 Modan B, Cuckle H, Lubin F. A note on the role of dietary retinol and carotene in human gastro-intestinal cancer. Int J Cancer 1981;28:421-424.

52 Cuckle HS, Kinlen LJ. Coffee and cancer of the pancreas. Brit J Cancer 1981;44:760-761. 53 Barlow RD, Wald NJ, Cuckle HS. A simple method for amniotic fluid acetylcholinesterase determination

suitable for routine use in the antenatal diagnosis of open neural-tube defects. Clin Chim Acta 1982;119:137-142.

54 Wald NJ, Cuckle HS. Pranatale diagnostik von neuralrohrdefekten. Laboratoriumsblatter 1981;1:27-41. 55 Wald NJ, Cuckle HS. Survival of infants with open spina bifida in relation to maternal serum alpha-fetoprotein

level. Third Report of the UK Collaborative Study on Alpha-Fetoprotein in Relation to Neural Tube Defects. Brit J Obstet Gynaecol 1982;89:3-7.

56 Wald NJ, Cuckle HS. Estimating an individual's risk of having a fetus with open spina bifida and the value of

7

repeat alpha-fetoprotein testing. Fourth Report of the U.K. Collaborative Study on Alpha-Fetoprotein in relation to Neural Tube Defects. J Epid Comm Hlth 1982;36:87-95.

57 Cuckle HS, Wald NW. Evidence against oral contraceptives as a cause of neural tube defects. Brit J Obstet Gynaecol 1982;89:547-549.

58 Wald NJ, Cuckle HS. Nomogram for estimating an individual's risk of having a fetus with open spina bifida. Brit J Obstet Gynaecol 1982;89:598-602.

59 Cuckle HS. I componenti del fumo di tabacco: esiste la sigaretta meno tossica? Min Med 1982;73:2397-2404. 60 Barlow RD, Cuckle HS, Wald NJ, Rodeck CH. False positive gel acetylcholinesterase results in blood-stained

amniotic fluids. Brit J Obstet Gynaecol 1982;89:821-826. 61 Wald NJ, Cuckle HS, Boreham J. Turnbull AC. Effect of estimating gestational age by ultrasound

cephalometry on the specificity of alpha-fetoprotein screening for open neural tube defects. Brit J Obstet Gynaecol 1982; 89:1050-1053.

62 Wald NJ, Cuckle HS. NTD screening by ultrasound. Lancet 1983;ii:459. 63 Cuckle HS, Parish SE, Galton DAG, Peto R, Hughes RG. Randomised trial of splenectomy in Ph1-positive

chronic granulocytic leukaemia, including an analysis of prognostic features. Brit J Haematol 1983;54:415-430.

64 Cuckle HS, Wald NJ. Principles of screening. In: Antenatal and Neonatal Screening for Disease. (Ed N Wald), Oxford University Press, 1-22, 1984.

65 Wald NJ, Cuckle HS. Open neural tube defects. In: Antental and Neonatal Screening for Disease. (Ed N Wald), Oxford University Press, 25-73, 1984.

66 Cuckle HS. Recurrence risk of neural tube defects following a miscarriage. Prenat Diagn 1983;3:287-289. 67 Kinlen LJ, Cuckle HS. Screening for cancer of the cervix. In: Antenatal and Neonatal Screening for Disease.

(Ed N Wald), Oxford University Press, 411-419, 1984. 68 Wald NJ, Cuckle HS. Neural tube defects: Screening and biochemical diagnosis. In: Prenatal Diagnosis -

Proceedings of the Eleventh Study Group of the Royal College of Obstetrics and Gynaecology. (Eds CH Rodeck, KH Nicolaides). R.C.O.G., London, 219-241, 1984.

69 Wald NJ, Cuckle HS, Boreham J. Alpha-fetoprotein screening for open spina bifida: effect of routine biparietal diameter measurement to estimate gestational age. Revue d'Epidemiologie et de Sante Publique 1984;32:62-69.

70 Klingberg M, Cuckle H, Chemke J, Papier C. The aetiology of central nervous system malformations. In: Neuro-behavioural Teratology. (Ed J Yanai), Elsevier Biomedical Press, 73-92, 1984.

71 Cuckle HS. The possible aetiological role of vitamin suppressing drugs in CNS malformations. In: Neuro-behavioural Teratology. (Ed J Yanai), Elsevier Biomedical Press, 389-401, 1984.

72 Steer HW, Cuckle HS, Frankelin PM, Morris PJ. The influence of diabetes mellitus on the outcome of patients presenting with rest pain, ulceration and gangrene of the lower leg. Are minor amputations worthwhile? Surgery, Gynaecology and Obstetrics 1983 ;157:64-72.

73 Cuckle HS, Wald NJ, Lindenbaum RH. Maternal serum alpha-fetoprotein measurement: a screening test for Down syndrome. Lancet 1984;i:926-929.

74 Barlow RD, Cuckle HS, Wald NJ. The identification of false positive amniotic fluid acetylcholinesterase results due to fetal calf serum contamination. Brit J Obstet Gynaecol 1984;91:986-988.

75 Wald NJ, Barlow RD, Cuckle HS, Turnbull AC, Goldfine C, Haddow J. Ratio of amniotic fluid acetylcholinesterase to pseudocholinesterase as an antenatal diagnostic test for exomphalos and gastroschisis. Brit J Obstet Gynaecol 1984;91:882-884.

76 Cuckle HS, Wald NJ, Lindenbaum RH, Jonasson J. Amniotic fluid AFP levels and Down syndrome. Lancet 1985; i:290-291.

77 Low maternal serum alpha-fetoprotein and Down syndrome. (Unsigned leading article written jointly with NJ Wald). Lancet 1985;i:259-260.

78 Wald NJ, Cuckle HS. Alpha-fetoprotein in the antenatal diagnosis of neural tube defects. In: Contemporary Obstetrics. (Ed G Chamberlain), Butterworths, 165-185, 1984.

79 Cuckle HS, Van Vunakis H. The effectiveness of a postal smoking 'kit'. Comm Med 1984;6:210-215. 80 Moroz C, Kan M, Chaimof C, Marcus H, Kupfer B, Cuckle HS. Ferritin bearing lymphocytes (FBL) in the

diagnosis of breast cancer. Cancer 1985;54:84-89. 81 Cuckle HS. Interpreting AFP and AChE results in blood-stained amniotic fluid samples. In: Prevention of

Physical and Mental Congenital Defects. (Ed M Marois), Alan Liss, NY, 213-217, 1985. 82 Cuckle HS. A methodology for studying the effects of industrial exposure on adverse pregnancy outcome. In:

8

Prevention of Physical and Mental Congential Defects. (Ed M Marois), Alan Liss, NY, 269-272, 1985. 83 Cuckle HS, Wald NJ, Lindenbaum RM. Screening for Down's syndrome using serum alpha-fetoprotein. Brit

Med J 1985; 291:349. 84 Terzian E, Boreham J, Cuckle HS, Wald NJ, Bobrow M, Lindenbaum R, Turnbull AC. A survey of diagnostic

amniocentesis in Oxford from 1974-1981. Prenat Diagn 1985;5:401-414. 85 Wald NJ, Cuckle HS, Nanchahal K, Turnbull AC. Sex difference in fetal size in early pregnancy. Brit Med J

1986;292:137. 86 Cuckle HS, Wald NJ. Recent developments in the prevention of neural tube defects in the United Kingdom.

In: Alpha-fetoprotein and Congenital Congenital Disorders. (Ed GJ Mizejewski, IH Porter), Academic Press, NY, 263-283, 1985.

87 Wald NJ, Cuckle HS, Barlow RD, Thompson P, Nanchahal K, Blow RJ, Brown I, Harling CC, McCulloch WJ, Morgan J, Reid AR. The effect of vitamin A supplementation on serum retinol and retinol binding protein levels. Cancer Letters 1985;29:203-213.

88 Peto J, Cuckle HS, Doll R, Herman C, Morgan LG. Respiratory cancer mortality of Welsh nickel refinery workers. In: Nickel in the Human Environment. (Ed FW Sunderman), IARC, Lyon, 37-46, 1984.

89 Cuckle HS, Wald NJ. Cord serum alpha-fetoprotein and Down's syndrome. Brit J Obstet Gynaecol 1986; 93:408-410.

90 Barlow RD, Thompson SG, Cuckle HS, Wald NJ, Voller A. Comparison of an ELISA with a RIA method for serum alpha-fetoprotein determination in screening for fetal neural tube defects. Ann Clin Bioch 1986;23:334-339.

91 Cuckle H. AFP screening for Down syndrome. Genetics Digest 1985:6-7. 92 Cuckle H. Prevention of spina bifida. Proceedings of the Third Congress of the International Federation for

Hydrocephalus and Spina Bifida, 9-11, Manchester, 1986. 93 Cuckle H. Screening for Down syndrome. Down syndrome Papers and Abstracts for Professionals

1986;9:5-6. 94 Cuckle HS, Wald NJ. Amniotic fluid alpha-fetoprotein levels in Down syndrome. Lancet 1986;ii:290-291. 95 Wald N, Cuckle H. Ultrasound biparietal diameter in spina bifida. Lancet 1986;ii:454. 96 Cuckle HS, Wald NJ, Butler EB. Compliance with screening for colorectal cancer. Brit Med J 1986;293:628. 97 Wald NJ, Nanchahal K, Thompson SG, Cuckle HS. Does breathing other people's tobacco smoke cause lung

cancer? Brit Med J 1986;293:1217-1222. 98 Wald NJ, Cuckle HS, Boreham J, Stirrat GM, Turnbull AC. Maternal serum AFP and low birth weight in

relation to gestational age. Brit J Obstet Gynaecol 1982;89:216-217. 99 Haddow JE, Palomaki GE, Wald NJ, Cuckle HS. Maternal serum alpha-fetoprotein screening for Down

syndrome and repeat testing Lancet 1986;ii:1460. 100 Cuckle H. Design of Clinical Trials. In: Leukaemia (Eds JA Whittaker, IW Delamore), Blackwell Scientific

Publications, Oxford, 1987. 101 Cuckle H, Wald N. The impact of screening for open neural tube defects in England and Wales. Prenat

Diagn 1987; 7:91-99. 102 Wald N, Frost C, Cuckle H, Oppenheimer P. Breast cancer screening. Lancet 1987;i:859. 103 Cuckle HS, Wald NJ. The effect of estimating gestational age by ultrasound cephalometry on the sensitivity of

alpha-fetoprotein screening for Down's syndrome. Brit J Obstet Gynaecol 1987;94:274-276. 104 Cuckle HS, Wald NJ, Thompson SG. Estimating a woman's risk of having a pregnancy associated with

Down's syndrome using her age and serum alpha-fetoprotein level. Brit J Obstet Gynaecol 1987;94:387-402.

105 Cuckle H. Defining the hazards of passive smoking. Modern Med 1987;32:547. 106 Cuckle H, Wald N. Low maternal serum alpha-fetoprotein and Down syndrome. Prenat Diagn

1987;7:611-612. 107 Cuckle HS, Nanchahal K, Wald NJ. Maternal serum alpha-fetoprotein and ethnic origin. Brit J Obstet

Gynaecol 1987;94:1111-1112. 108 Cuckle H, Wald N. Vaginal bleeding in pregnancies associated with fetal Down syndrome. Prenat Diagn

1987; 7:619-622. 109 Cuckle H. Screening for neural tube defects. In: Prevention of mental handicap: a world view (Eds G

Hosking, G Murphy), Royal Society of Medicine Services International Congress and Symposium Series No. 112, pp 41-44 Royal Society of Medicine, 1987.

110 Wald N, Cuckle H. Recent advances in screening for neural tube defects and Down syndrome. In: Prenatal

9

Diagnosis of Genetic Defects (Ed CH Rodeck), Bailliere Tindall, London, 1987. 111 Canick JA, Knight GJ, Palomaki GE, Haddow JE, Cuckle HS, Wald NJ. Low second trimester maternal

serum unconjugated oestriol in pregnancies with Down's syndrome. Brit J Obstet Gynaecol 1988;95:330-333.

112 Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Canick JA, Haddow JE, Knight GJ, Palomaki G. Maternal serum unconjugated oestriol as an antenatal screening test for Down's syndrome. Brit J Obstet Gynaecol 1988;95:334-341.

113 Cuckle H, Wald N, Thompson S. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Brit J Obstet Gynaecol 1987;94:1225-1228.

114 Cuckle HS, Wald N, Stone R, Densem J, Haddow J, Knight G. Maternal serum thyroid antibodies in early pregnancy and fetal Down's syndrome. Prenat Diagn 1988;8:439-445.

115 Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P, Chard T, Haddow JE, Knight GJ, Palomaki G, Canick JA. Maternal serum screening for Down syndrome in early pregnancy. Brit Med J 1988;297:883-887.

116 Cuckle HS, Wald NJ, Barkai G, Fuhrmann W, Atland K, Brambati B, Knight G, Palomaki G, Haddow JE, Canick J. First trimester biochemical screening for Down's syndrome. Lancet 1988;ii:851-852.

117 Cuckle HS, Wald NJ. Britain's chance to get screening right. New Scientist 1988;1634:48-51. 118 Wald N, Cuckle H, Royston P. Antenatal screening for Down syndrome. Lancet 1988;ii:1362. 119 Cuckle H, Igor and Inna Uspensky. Lancet 1988;ii:1372. 120 Wald NJ, Cuckle HS. AFP and Age Screening for Down syndrome. Am J Med Genet 1988;31:197-209. 121 Wald NJ, Cuckle HS, Densem JW, Nanchahal K, Royston P. Serum screening for Down's syndrome. Brit

Med J 1989; 298:50. 122 Cuckle HS, Wald NJ, Nanchahal K, Densem J. Repeat maternal serum testing in antenatal screening

programmes for Down syndrome. Brit J Obstet Gynaecol 1989;96:52-60. 123 Cuckle H. Health hazards of passive smoking. Postgraduate Update 1989;38:142-146. 124 Wald NJ, Cuckle HS. Reporting the assessment of screening and diagnostic tests. Brit J Obstet Gynaecol

1989; 96:389-396. 125 Wald NJ, Cuckle HS, Sneddon J, Haddow JE, Palomaki GE. Screening for Down syndrome. Am J Hum

Genet 1989; 44:586-587. 126 Cuckle HS, Wald NJ, Cuckle P. Antenatal diagnosis of neural tube defects in England and Wales. Prenat

Diagn 1989;9:393-400. 127 Wald NJ, Cuckle HS. Maternal serum screening for neural tube defects and Down's syndrome. Clin Genet

Bull 1989; 2(3):43-53. 128 Wald N, Cuckle H, Densem J. Maternal serum specific beta1-glycoprotein levels in pregnancies associated

with Down's syndrome. Lancet 1989;ii:450. 129 Wald NJ, Cuckle HS. Biochemical detection of neural tube defects and Down's syndrome. In: Textbook of

Obstetrics, (Eds A Turnbull, G Chamberlain) Churchill Livingstone, Edinburgh, 269-289, 1989. 130 Wald NJ, Cuckle HS. AFP Screening in Early Pregnancy. In: Fetal Monitoring, (Ed JAD Spencer), Castle

House Publications, Tunbridge Wells, 41-45, 1989. 131 Cuckle HS, Wald NJ. The evaluation of screening tests for ovarian cancer. In: Ovarian Cancer (eds. Sharp F,

Mason P, Leake R), Chapman & Hall, London, 229-239, 1990. 132 Cuckle HS, Wald NJ. Ovulation induction and neural tube defects. Lancet 1989;ii:1281. 133 Wald NJ, Cuckle HS, Nanchahal K. Amniotic fluid acetylcholinesterase measurement as a primary diagnostic

test for open nueral tube defects. Second report of the Collaborative Acetylcholinesterase Study. Prenat Diagn 1989;9:813-829.

134 Cuckle HS, Wald NJ, Quinn J, Royston P, Butler L. Ultrasound fetal femur length measurement in the screening for Down syndrome. Brit J Obstet Gynaecol 1989; 96:1373-1378.

135 Cuckle HS, Wald NJ. Ovulation induction and neural tube defects. Lancet 1990;i:178. 136 Cuckle HS, Densem JW, Wald NJ. Simplification of biochemical screening for Down syndrome. Am J Hum

Genet 1989;45:979-980. 137 Cuckle HS, Wald NJ, Hughes DR. Cord serum alphafetoprotein and maternal insulin-dependent diabetes

mellitus. Brit J Obstet Gynaecol 1989;96:1450-1452. 138 Wald NJ, Nanchahal K, Cuckle HS, Thompson S. Lung cancer and passive smoking. Brit J Cancer

1990;61:337-344. 139 Cuckle H, Wald N, Stevenson JD, May HM, Ferguson-Smith MA, Milford Ward A, Barbour HM, Laurence

10

KM, Norgaard-Pedersen B. Maternal serum alpha-fetoprotein screening for open neural tube defects in twin pregnancies. Prenat Diagn 1990;10:71-77.

140 Cuckle H, Wald N. Biochemical Screening. Current Opinions in Obstet & Gynaecol 1990;2:246-252. 141 Cuckle H, Wald N, Densem J, Royston P, Knight G, Haddow J, Palomaki G, Canick J. The effect of smoking

in pregnancy on maternal serum alpha-fetoprotein, unconjugated oestriol, human chorionic gonadotrophin, progesterone and dehydroepiandrosterone sulphate levels. Brit J Obstet Gynaecol 1990;97:272-276.

142 Cuckle H, Stone R, Smith D, Wald N. Dehydroepiandrosterone sulphate in Alzheimer's disease. Lancet 1990;ii:449-450.

143 Rasmussen Loft AG, Nanchahal K, Cuckle HS, Wald NJ, Hulten M, Norgaard-Pedersen B. Amniotic fluid acetylcholinesterase in the antenatal diagnosis of open neural tube defects and abdominal wall defects: a comparison of gel eletrophoretis and a monoclonal antibody immunoassay. Prenat Diagn 1990;10:449-459.

144 Cuckle HS, Wald NJ. Screening for Down syndrome. In: Prenatal Diagnosis and Prognosis, (Ed RJ Lilford), Butterworth, London, 67-92, 1990.

145 Cuckle HS. Screening with discrimination: Arguments for a national screening body. Br Med J 1990;301:889-890.

146 Cuckle HS, Alberman E, Wald NJ, Royston P, Knight G. Cigarette smoking and Down syndrome. Prenat Diagn 1990; 10:561-567.

147 Haddow JE, Palomaki GE, Knight GJ, Canick JA, Wald NJ, Cuckle HS. Maternal serum unconjugated oestriol levels are lower in the presence of fetal Down syndrome. Am J Obstet Gynecol 1990;162:1372.

148 Cuckle HS, Wald NJ, Goodburn SF, Sneddon J, Amess JAL, Carlson Dunn S. Maternal urea-resistant neutrophil alkaline phosphatase determination as a screening test for Down's syndrome. Br Med J 1990;301:1024-1026.

149 Cuckle H, Wald N. The use of AFP and other markers for NTD and Down's syndrome. Proceedings of the EQAS 1990 Meeting, Cardiff, 1990.

150 Wald N, Cuckle H. Biochemical screening for Down's syndrome. In: The Embryo - Normal and Abnormal Development and Growth. (Ed. Chapman M, Grudzinskas G, Chard T.) 1991;pp 251-7.

151 Cuckle H, Nanchahal K, Wald N. Birth prevalence of Down's syndrome in England and Wales. Prenat Diagn 1991;11:29-34.

152 Wald NJ, Cuckle HS, Haddow JE, Doherty RA, Knight GJ, Palomaki GE. Sensitivity of ultrasound in detecting spina bifida. NEJM 1991;321:769-770.

153 Cuckle H. Breast cancer screening by mammography: an overview. Clin Radiology 1991;43:77-80. 154 Wald N, Frost C, Cuckle H. Breast cancer screening: the current position. Br Med J 1991;302:845-846. 155 Cuckle H, Jones N, Kay J, Standing S. Maternal serum alpha-fetoprotein in congenital hypothyroidism.

Lancet 1991;337:922. 156 Wald N, Cuckle H. Some Practical Issues in the Antenatal detection of Neural Tube Defects and Down's

Syndrome. In: Antenatal Diagnosis of Fetal Abnormalities (Eds. Drife JO, Donnai D), Springer-Verlag, London, 1991;45-57.

157 Wald N, Densem J, Kennard A, Cuckle H. Estimating risk of Down's syndrome. Br Med J 1991;302:1536. 158 Cuckle H, Wald N, Densem J. Estimating risk of Down's syndrome, Br Med J 1991;303:312. 159 Cuckle H, Lilford RJ, Thornton JG. Prenatal screening for Down's syndrome, Br Med J 1991;303:312. 160 Cuckle H, Wald N. Screening for ovarian cancer. In: Cancer Screening, (Eds A B Miller, J Chamberlain, N E

Day, M Hakama, P C Prorok), Cambridge University Press, 1991 pp 228-239. 161 Wald N, Cuckle H, Wu T, George L. Maternal serum unconjugated oestriol and human chorionic

gonadotrophin levels in twin pregnancies: implications for screening for Down's syndrome. Br J Obstet Gynaecol 1991;98:905-908.

162 Wald N, Cuckle H, Nanchahal K, Thompson S. Response to letter from Dr. Lee. Br J Cancer 1991;64:201. 163 Cuckle HS, Wald NJ, Densem, Canick J, Abell KB. Second trimester amniotic fluid oestriol,

dehydroepiandrosterone sulphate, and human chorionic gonadotrophin levels in Down's syndrome. Br J Obstet Gynaecol 1991;98:1160-1162.

164 Wald NJ, Cuckle HS, Densem JW, Stone RB. Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in pregnancies with insulin-dependent diabetes: implications for screening for Down's syndrome. Br J Obstet Gynaecol 1992;99:51-53.

165 Cuckle H. Antenatal Diagnosis. The Practitioner 1992; 235:308-312. 166 Wald NJ, Cuckle HS, Densem JW, Kennard A, Smith D. Maternal Serum Screening for Down's Syndrome:

The Effect of Routine Ultrasound Scan Determination of Gestational Age and Adjustment for Maternal

11

Weight. Br J Obstet Gynaecol 1992;99:144-149. 167 Cuckle H. Screening for osteoporosis. Lancet 1992 339:680. 168 Cuckle HS, Wald NJ. Biochemical screening for Down's syndrome. In: Early Fetal Diagnosis: Recent

Progress and Public Health Implication (Eds Macek M, Ferguson-Smith MA, Spála M), Karolinum - Charles University Press, Prague, 1992.

169 Wald N, Cuckle HS, Grudzinskas JG, Barkai G, Brambati B, Teisner B, Fuhrmann W. First trimester concentrations of pregnancy associated plasma protein A and placental protein 14 in Down's syndrome. Br Med J 1992;305:28.

170 Cuckle HS, Densem JW, Wald NJ. Detection of hydatidiform mole in maternal serum screening programmes for Down's syndrome. Br J Obstet Gynaecol 1992;99:495-497.

171 Mason G, Linton G, Cuckle H, Holding S. Low maternal serum human chorionic gonadotrophin and unconjugated oestriol in a triploidy pregnancy. Prenatal Diagnosis 1992;12:545-547.

172 Cuckle HS. Aneuploidy indices in biochemical screening. Prenatal Diagnosis 1992;12:545. 173 Wald NJ, Kennard A, Densem JW, Cuckle HS, Chard T, Butler L. Antenatal maternal serum screening for

Down's syndrome: results of a demonstration project. Br Med J 1992; 305:391-394. 174 Cuckle H, Lilford RJ, Teisner B, Holding S, Chard T, Grudzinskas JG. Pregnancy associated plasma protein

A in Down's syndrome Br Med J 1992;305:425. 175 Cuckle H. Maternal serum screening policy for Down's syndrome. Lancet 1992;340:799. 176 Cuckle HS. The effect of gestational age on maternal serum -fetoprotein levels in pregnancies with Down's

syndrome. Am J Obstet Gynecol 1992;167:569. 177 Miller D, Tang P.-Z, Cartmill R.S.V, Griffith-Jones M.D, Lilford RJ, Cuckle HS. Semi-quantitative detection

of Down's syndrome with PCR. Lancet 1992;340:620-621. 178 Cuckle HS. Measuring unconjugated estriol in maternal serum to screen for fetal Down syndrome. Clin Chem

1992;38:1687-1689. 179 Cuckle HS. Design of Clinical Trials. In: Leukaemia (second edition). (Ed. Dr. J. A. Whittaker), Blackwell

Scientific Publications Ltd., Oxford, 1992;651-660. 180 Cuckle H, Lilford R. Antenatal screening for Down's syndrome. Br Med J 1992;305:1017. 181 Black MM, Modan B, Lubin F, Triffleman E, Cuckle H, Rosen N, Kwon CS, Peretz M, Alfandary E. A

nationwide study of breast disease. Cancer 1988;61(12):2547-2551. 182 Wald NJ, Cuckle HS. Antenatal screening and diagnosis. In: Epidemiology and Control of Neural Tube

defects, (Eds JM Elwood, J. Little, JH Elwood), Oxford University Press, Oxford, 1992;711-726. 183 Cuckle H. Screening for Down's syndrome. Br Med J 1992;305:1504. 184 Cuckle HS, Wald NJ. HCG, estriol, and other maternal blood markers of fetal aneuploidy. In: Maternal Serum

Screening For Fetal Genetic Disorders. (Eds Elias S & Simpson JL), Churchill-Livingstone, New York, 1992;87-105.

185 Wald NJ, Cuckle HS, Biochemical Screening. In: Prenatal Diagnosis and Screening. (Eds. Brock DJH, Rodeck CH & Ferguson-Smith MA. Churchill Livingstone, Edinburgh. 1992;pp563-577.

186 Wald NJ, Cuckle HS. Complementary Use of Biochemical Tests and Ultrasonography for Detection of Neural Tube Defects and Down's Syndrome: Screening. In: Ultrasound in Obstetrics and Gynecology: Vol 2. (Eds Chervenak FA, Isaacson GC, Campbell S), Little, Brown. Boston. 1993;pp1135-1143.

187 Cuckle HS, Wald NJ. Complementary Use of Biochemical Tests and Ultrasonography for Detection of Neural Tube Defects and Down's Syndrome: Diagnosis. In: Ultrasound in Obstetrics and Gynecology: Vol 2. (Eds Chervenak FA, Isaacson GC, Campbell S), Little, Brown. Boston. 1993;pp1145-1150.

188 Mason G, Lindow S, Ramsden C, Cuckle H and Holding S. Low maternal serum oestriol and chorionic gonadotropin in the prediction of adverse pregnancy outcome. Prenat Diagn 1993;13:223-225.

189 Cuckle H, Lilford R. Antenatal screening for Down's syndrome. Br Med J 1993;306:1199. 190 Cuckle H S. Sex differences in the location of a spina bifida lesion. J Med Genet 1993;30:262-263 191 Kennedy RL, Jones TH, Cuckle HS. Down's Syndrome and the thyroid. Clin Endocrin 1992;37:471-476. 192 Muller F, Cuckle H, Teisner B, Grudzinskas JD. Serum PAPP-A levels are depressed in women with fetal

down syndrome in early pregnancy. Prenat Diagn 1993;13:633-636. 193 Barkai G, Goldman B, Ries L, Chaki R, Zer T, Cuckle H. Expanding multiple marker screening for Down's

syndrome to include Edward's syndrome. Prenat Diagn 1993;13:843-850. 194 Cuckle H. Cystic fibrosis screening strategies. Br J Hosp Med 1993;50:398-402. 195 Cuckle HS. Utility of unconjugated oestriol in screening for Down's syndrome is not proven. Clin Chem

1993;39:2025-2026.

12

196 Cuckle H. A woman's right to a screen test. The Guardian, December 7th, 1993. 197 Cuckle H. Screening for Disease: Benefit or Burden? University of Leeds Review 1993;36:75-88. 198 Cuckle HS. Screening for Neural Tube Defects. In: Neural Tube Defect (Ciba Foundation Symposium 181).

Wiley Chichester, 1994;pp253-269. 199 Cuckle HS, Jones RG. Maternal serum free β-human chorionic gonadotrophin level: the effect of sample

transportation. Ann Clin Biochem 1994;31:97-98. 200 Cuckle HS, Lilford RJ, Jones R. Maternal serum screening for Down's syndrome before 15 weeks. Am J

Obstet & Gynaecol 1994;170(3):959. 201 Holding S, Cuckle, HS. Maternal serum screening for Downs syndrome taking account of the result in a

previous pregnancy. Prenat Diagn 1994;14:321-322. 202 Cuckle H. Rational Down's syndrome screening policy. Eur. J Pub Health 1994;4:77-78. 203 Cuckle HS, Holding S, Jones R. Maternal serum Inhibin levels in second trimester Down's syndrome

pregnancies. Prenat Diagn 1994;14:387-390. 204 Cuckle H, Densem J, Wald N. Repeat maternal serum testing in multiple marker Down's syndrome screening

programmes. Prenat Diagn 1994;14:603-607. 205 Snijders RJM, Holzgreve W, Cuckle H, Nicolaides KH. Maternal Age-specific Risks for Trisomies at 9-14

Weeks Gestation. Prenat Diagn 1994;14:543-552. 206 Cuckle H. Multimarker Screening for Down's Syndrome. The Diplomate 1994;1(2):104-109. 207 Cuckle H. Breast Cancer Screening for Women Aged Under 50 with a Significant Family History. Oncology

Newsletter (Journal of the Yorkshire Regional Cancer Organisation) 1994;17:13-14. 208 Ind TEJ, Iles RK, Cuckle HS, Chard T. Second trimester maternal serum placental alkaline phosphatase

concentrations in Down's syndrome. J Obstet & Gynaecol 1994;14:305-308. 209 Cuckle H. Risk estimation in Down's syndrome screening policy and practice. In: Screening for Down's

syndrome. (Eds. JG Grudzinskas, T Chard, M Chapman, H Cuckle). Cambridge University Press, UK. 1994;pp31-46.

210 Cuckle H. Screening at 11-14 weeks gestation: the role of established markers and PAPP-A. In: Screening for Down's syndrome. (Eds. JG Grudzinskas, T Chard, M Chapman, H Cuckle). Cambridge University Press, UK. 1994;pp311-322.

211 Cuckle HS, Iles RK, Chard T. Urinary -Core human chorionic gonadotrophin: A new approach to Down's syndrome screening. Prenat Diagn 1994;14:953-958.

212 Cuckle H, van Oudgaarden ED, Mason G, Holding S. Taking account of vaginal bleeding in screening for Down’s syndrome. Br J Obstet Gynaecol 1994;101:948-953.

213 Cuckle HS, Thornton JG. Antenatal diagnosis and management of neural tube defects. In: Fetal and Neonatal Neurology and Neurosurgery. (Eds. Malcolm I. Levene, Richard J Lilford). Churchill Livingstone, London, UK. 1995;pp295-309

214 Cuckle H. Associations de marquers biochimiques dans la T21. Médecine Foetale et Echographie en Gynécologie 1994; 20:64-66.

215 Cuckle HS. A rational screening policy for Down's syndrome. Eur J Pub Health 1995;5(1):60-61. 216 Cuckle HS, Holding S, Jones R, Wallace EM, Groome NP. Maternal serum dimeric inhibin A in second

trimester Down's syndrome. Prenat Diagn 1995;15(4):385-386 217 Findlay I, Cuckle H, Lilford RJ, Rutherford AJ, Quirke P, Lui S. Screening Sperm Donors for Cystic Fibrosis.

Br Med J 1995;310:1533. 218 Cuckle HS. Down's Syndrome Screening: the use of models in risk calculation, formulating policy, informing

users and quality assessment. Proceedings of the UK NEQAS Meeting 1994;1:112-119. 219 Cuckle HS, Ellis AR, Seth J. Provision of screening for Down's syndrome. BMJ 1995;311:512. 220 Cuckle HS, Iles RK, Sehmi IK, Chard T, Oakey RE, Davies S, Ind T. Urinary multiple marker screening for

Down's syndrome. Prenat Diagn 1995;15:745-751. 221 Cuckle H, Lilford R, Wilson J, Sehmi I. Direct marketing of cystic fibrosis carrier screening: commercial push

or population need. J Med Genet 1995;32:758. 222 Cuckle H. Screening for Ovarian Cancer. In: Evaluation of Cancer Screening (Eds. Jocelyn Chamberlain &

Sue Moss) Springer-Verlag UK. 1995;pp95-115. 223 Cuckle HS, Jones RG. Posting maternal blood samples for free -human chorionic gonadotrophin testing.

Prenat Diagn 1995;15:879-880. 224 Holding S, Cuckle H. Full blood count and second-trimester markers of Down's syndrome. Prenat Diagn

1995;15(10):982-984.

13

225 Cuckle H. Improved parameters for risk estimation in Down's syndrome screening. Prenat Diagn 1995;15:1057-1065.

226 Cuckle HS, Richardson GA, Sheldon TA, Quirke P. Cost-effectiveness of antenatal screening for cystic fibrosis. Br Med J 1995;311:1460-1463.

227 Cuckle H. Opinion. Biochemical and ultrasound screening for Down's syndrome: rivals or partners? Ultrasound in Obstet Gynecol 1996;7:236-238.

228 Cuckle HS, Richardson GA, Sheldon TA, Quirke P. Cost effectiveness of antenatal screening for cystic fibrosis. Br Med J 1996;312:908-910.

229 Murray J, Sehmi I, Cuckle H. Identifying genetic risk. Brit J Family Planning 1996;22:57. 230 Barkai G, Goldman B, Ries L, Chaki R, Cuckle H. Effect of Gravidity on Maternal Serum Markers for Down

Syndrome. Prenat Diagn 1996:16;319-322. 231 Cuckle H. Screening for Breast Cancer in Young Women. In: Evidence Guided Prescribing of the Pill. (Eds.

PC Hannaford and AMC Webb). The Parthenon Publishing Group. UK. 1996;pp209-215. 232 Cuckle H, Quirke P, Sehmi I, Lewis F, Wilson J, Cross D, Cuckle P, Ozols B. Antenatal screening for cystic

fibrosis. Brit J Obstet Gynaecol 1996;103:795-799. 233 Barkai G, Goldman B, Ries L, Chaki R, Cuckle H. Ethnic origin and maternal serum markers of Down's

syndrome in Israel. Prenat Diagn 1996;16:870-872. 234 Cuckle H, Sehmi I, Holding S. Nomograms to help inform women considering Down's syndrome screening.

Eur J Obstet & Gynaecol and Reprod Biology 1996;69:69-72. 235 Cuckle HS, Thornton JG. Aneuploidy risk with isolated choroid plexus cysts. Prenat Diagn 1996;16:967-

972. 236 Cuckle H. Risk estimation in Down’s syndrome screening. Prenat Diagn 1996;16:1056-1057. 237 Cuckle HS, Canick JA, Kellner LH, van Lith JMM, White I, Helbig BR, Rose NC, Sehmi IK, Jones R.

Urinary -core hCG screening in the first trimester. Prenat Diagn 1996;16:1057-1059. 238 Tafas T, Evans MI, Cuckle HS, Nasr S, Krivchenia EL, Resvani E, Tsipouras P. An automated image analysis

method for the measurement of neutrophil alkaline phosphatase in the prenatal screening of Down syndrome. Fetal Diagnosis & Therapy 1996;11:254-260.

239 Cuckle HS, Holding S, Jones R, Groom NP, Wallace EM. Combining inhibin A with existing second-trimester markers in maternal serum screening for Down's syndrome. Prenat Diagn 1996;16:1095-1100.

240 Barkai G, Goldman B, Ries L, Chaki R, Dor J, Cuckle H. Down's syndrome screening marker levels following assisted reproduction. Prenat Diagn 1996;16:1111-1114.

241 Cuckle H. Evaluation of screening programmes. In: Evidence-Based Obstetrics and Gynaecology. (Eds. IE Cooke and DL Sackett). Baillière's Clinical Obstetrics and Gynaecology 1996;10(4):631-645. Baillière Tindall, London.

242 Cuckle H. Established markers in second trimester maternal serum. Early Human Development 1996;47 Suppl:27-29.

243 Cole L, Isozaki T, Palomaki G, Canick J, Iles R, Kellner L, Saller D, Cuckle H. Detection of -core fragment in second trimester Down's syndrome pregnancies. Early Human Development 1996;47 Suppl:47-48.

244 Murray J, Cuckle H, Taylor G, Hewison J. Screening for fragile X syndrome. Health Technology Assessment 1997; 1(4):1-71.

245 Cuckle H. Epidemiology of Down's syndrome. In: Screening for Down's syndrome in the first trimester. Eds. J.G. Grudzinskas and R.H.T. Ward. RCOG Press, London, UK. 1997;pp3-13.

246 Cuckle H. Book review. When to Screen in Obstetrics and Gynaecology. Br J Obstet Gynaecol 1997;104;872. 247 Murray J, Cuckle H, Taylor G, Hewison J. Screening for fragile X syndrome; information needs for health

planners. J Med Screening 1997;4:60-94. 248 Cuckle H, Murray J. Epidemiology of ectopic pregnancy. In. Problems in early pregnancy: advances in

diagnosis and management. Eds. J.G. Grudzinskas and P.M.S. O’Brien. RCOG, London, UK. 1997;pp65-76.

249 Cuckle H. Second trimester screening markers: an overview. Cesko-Slovenská Pediatrie 1997;52(7):504-5. 250 Cuckle H. Fetal nuchal translucency test for Down’s syndrome. Lancet 1997;350:1629-30. 251 Cuckle H. Overview of antenatal screening for abnormality. Gynaecology Forum 1997;2(4):3-6. 252 Murray J, Cuckle H, Taylor G, Hewison J. Screening for fragile X. J Med Screening 1997;4:247. 253 Cuckle H. Down’s syndrome screening in twins. J Med Screening 1998;5:3-4. 254 Cuckle H. Rational Down syndrome screening policy. Am J Pub Health 1998;88(4):558-559. 255 Cuckle H, Miller D, Hossein Nia M, Gordon DJ, Holt DW. Isoenzymes of maternal serum alkaline

14

phosphatase in Down syndrome. Prenat Diagn 1998;18:405-415. 256 Cuckle H, Murray J. Screening for Cystic Fibrosis. Disease Management and Health Outcomes

1998;3(4):161-172. 257 Nicolaides KH, Snijders RJM, Cuckle HS. Correct estimation of parameters for ultrasound nuchal

translucency screening. Prenat Diagn 1998;18(5):519-523. 258 Cuckle HS, Murray J. Screening for genetic disease in pregnancy. In. Gene Identification, Manipulation and

Therapy. (Eds SK Smith, E Thomas and PMS O’Brien). RCOG, London, UK, 1998:pp 151-161. 259 Cuckle HS. Antenatal screening today and in the future. RCM Midwives Journal 1998;1(6):177-179. 260 Cuckle H. Antenatal screening. Seminars in Neonatology 1998;3:1-8. 261 Cuckle H. Screening for cancer in those at high risk as a result of genetic susceptibility. In: Inherited

susceptibility to cancer. (Ed. WD Foulkes, SV Hodgson). Cambridge University Press, 1998:pp 20-29. 262 Cuckle HS. Design of Clinical Trials and Biostatistical Methods. In: Leukaemia and Associated Disorders.

Third Edition (Eds. Holmes and Whittaker). Blackwell Scientific, UK, 1998:pp 544-551. 263 Macintosh M, Ellis A, Cuckle H, Seth J. Variation in biochemical screening for Down's Syndrome in the

United Kingdom. Brit J Obstet Gynaecol 1998:105;465-67. 264 Cuckle H. Antenatal screening for Down's syndrome. Lancet 1998;352:1144. 265 Cuckle H, Sehmi I, Jones R. Maternal serum inhibin A can predict pre-eclampsia. Brit J Obstet Gynaecol

1998;105: 1101-1103. 266 Iles RK, Black A, Gunn LK, Sehmi IK, Cuckle HS, Chard T. Measures of urine concentration in maternal

urine screening for Down syndrome. Prenat Diagn 1998;18:1006-1009. 267 Cuckle H. Effect of maternal age curve on the predicted detection rate in maternal serum screening for

Down syndrome. Prenat Diagn 1998;18:1127-1130. 268 Moss S, Cuckle H. Trial of mammography in women under 50 is ethical. Br Med J 1998;317:1589. 269 Canick JA, Kellner LH, Cole LA, Cuckle HS. Urinary analyte screening: a noninvasive detection method

for Down syndrome. Mol Med Today 1999;5(2):68-73. 270 Cuckle HS, Sehmi IK, Jones RG, Purves DA. Regression curves for maternal serum inhibin A. Prenat

Diagn 1999; 19:287-290. 271 Cuckle H. Overview of established and emerging screening techniques. In: Down Syndrome Screening

Policy and Economic Evaluations (Eds Beazoglou T, Benn P, Cuckle H, Haddow J, Kyriopoulos J). Exandas, Athens 1999:pp 29-42.

272 Cuckle H, Sehmi IK. Calculating correct Down’s syndrome risks. Brit J Obstet Gynaecol 1999;106:371-372.

273 Ferriman EL, Sehmi IK, Jones R, Cuckle HS. The effect of smoking in pregnancy on maternal serum inhibin A levels. Prenat Diagn 1999;19(4):372-374.

274 Cuckle H. Early Down’s syndrome screening is feasible. Trends in Urology, Gynaecology and Sexual Health 1999;4(3):11-12.

275 de Graaf IM, Prjkrt E, Bilardo CM, Leschot NJ, Cuckle HS, Van Lith JMM. Early pregnancy screening for fetal aneuploidy with serum markers and nuchal translucency. Prenat Diagn 1999;19(5):458-462.

276 Murray J, Cuckle H, Taylor G, Littlewood J, Hewison J. Screening for cystic fibrosis. Health Technology Assessment 1999;3(8):1-97.

277 Cuckle HS, van Lith JMM. Appropriate biochemical parameters in first trimester screening for Down’s syndrome. Prenat Diagn 1999;19(6):505-512.

278 Cuckle HS, Sehmi I, Jones R, Evans LW. Maternal serum activin A and follistatin levels in pregnancies with Down's syndrome. Prenat Diagn 1999;19(6):513-516.

279 Tsukerman GL, Gusina NB, Cuckle HS. Maternal serum screening for Down’s syndrome in the first trimester: experience from Belarus. Prenat Diagn 1999;19(6):499-504.

280 Cuckle HS, Sehmi IK, Jones R. Inhibin A and non-Down’s syndrome aneuploidy. Prenat Diagn 1999;19(8):787-788.

281 Cuckle HS, Sehmi IK, Jones R, Mason G. Low maternal serum PAPP-A and fetal viability. Prenat Diagn 1999;19(8):788-790.

282 Cuckle H. Maternal age-standardisation of Down’s syndrome prevalence. Lancet 1999;354:529-30. 283 Cuckle H. Screening for CF, when, who and how? Update 1999;59(3):178. 284 Cuckle H. Problems in the evaluation of medical screening programmes. In: Preventive Medicine: whose

responsibility? What should its limits be? (Eds Dormandy JA, Mittelstrass J) Ernst Schering Research Foundation 1999:pp 13-20.

15

285 Haslehurst J, Tucker A, Cuckle H. Occupational screening for breast cancer. Occupational Health Review 1999(Sept/Oct):1-4.

286 Cuckle HS, Shahabi S, Sehmi IK, Jones R, Cole LA. Maternal urine hyperglycosylated hCG in pregnancies with Down syndrome. Prenat Diagn 1999;19(10):918-920.

287 Cuckle HS, Canick JA, Kellner LH. Collaborative study of maternal urine -core human chorionic gonadotrophin screening for Down syndrome. Prenat Diagn 1999; 19(10):911-917.

288 Cuckle HS. Book Review: Should health screening be private? J Med Screen 1999;6(2):114. 289 Moss S, on behalf of the Trial Steering Group - Cuckle H, (Chairman), Anderson TJ, Asbury DL, Cohen M,

Evans A, Kutt E, Muir B, Record C, Roebuck E, Thomas BA, Thomas I, Twentyman P. A trial to study the effect on breast cancer mortality of annual mammographic screening in women starting at age 40. J Med Screen 1999;6(3):144-148.

290 Cambell J, Cuckle H, Sehmi I, Jones R. First trimester Down syndrome screening markers in triploidy: a case report. Prenat Diagn 1999;19(11):1086-1088.

291 Cuckle H. Down syndrome fetal loss rate in early pregnancy. Prenat Diagn 1999;19(12):1177-1179. 292 Maymon R, Sehmi IK, Herman A, Jones RG, Sherman D, Cuckle H. Serum inhibin A levels in pregnant

women with systemic lupus erythematosus or antiphospholipid syndrome. Prenat Diagn 2000;20(1):12-16. 293 De Graaf IM, Cuckle HS, Pajkrt E, Leschot NJ, Bleker OP, Van Lith JMM. Co-variables in first trimester

maternal serum screening. Prenat Diagn 2000;20(3):186-189. 294 Cuckle H. Antenatal screening for chromosomal and genetic abnormalities. In: The Yearbook of Obstetrics

and Gynaecology: volume 8. Ed. P.M. Shaughn O’Brien. RCOG, London, UK 2000; pp74-85. 295 Rajkhowa M, Glass MR, Rutherford AJ, Balen AH, Sharma V, Cuckle HS. Trends in the incidence of ectopic

pregnancy in England and Wales from 1966 to 1996. Brit J Obstet Gynaecol 2000;107:369-374. 296 Cuckle H, Arbuzova S. Maternal Blood Superoxide Dismutase in Down’s Syndrome. Prenat Diagn

2000;20(4):354-355. 297 Moroz C, Maymon R, Jauniaux E, Traub L, Cuckle H. Screening for trisomies 21 and 18 with maternal serum

placental isoferritin p43 component. Prenat Diagn. 2000;20(5):395-399. 298 Ferriman EL, Sehmi IK, Jones RG, Gordon Y, Cuckle HS. Serum Screening in a Japanese Population.

Prenat Diagn 2000;20(5):437-438. 299 Wald NJ, Hackshaw AK, Cuckle HS. Maternal serum alphafetoprotein screening for open neural tube

defects: revised statistical parameters. Br J Obstet Gynaecol. 2000;107:296-298. 300 Pesso R, Berkenstadt M, Cuckle H, Gak E, Peleg L, Frydman M, Barkai G. Screening for fragile X

syndrome in women of reproductive age. Prenat Diagn 2000;20:611-614. 301 Cuckle H. Statistical modelling is best tool for formulating screening policy. Br Med J 2000;321:762. 302 Cuckle H. Biochemical screening for Down syndrome. Eur J Obstet Gynecol Reprod Biol 2000;92:97-101. 303 Cuckle HS, Wald NJ. Principles of screening. In: Antenatal & neonatal screening, second edition. (Eds. N

Wald, I Leck). Oxford University Press, Oxford, 2000:pp3-22. 304 Ferriman EL, Sehmi IK, Jones R, Railton A, Hilton RC, Cuckle HS. False-positive maternal serum

screening in systemic lupus erythematosis: a case report. Prenat Diagn. 2000;20:851. 305 Moutsatsou P, Liakou K, Breen K, Cuckle H. The serum expression of sialyltransferase in normal and

Down syndrome affected pregnancy. Ann Clin Biochem 2000;37:507-511. 306 Miller D, Cuckle HS. A needle in a haystack: prenatal diagnosis of Down’s syndrome. Trends in Molecular

Medicine 2001;7(2):50. 307 Murray J, Cuckle H, Sehmi I, Wilson C, Ellis A. Quality of written information used in Down’s syndrome

screening. Prenat Diagn 2001;21(2):138-42. 308 Maymon R, Cuckle H, Sehmi IK, Herman A, Sherman D. Maternal serum human chorionic gonadotrophin

levels in systemic lupus erythematosus and antiphospholipid syndrome. Prenat Diagn 2001;21(2):143-45. 309 Hewison J, Cuckle H, Baillie C, Sehmi I, Lindow S, Jackson F, Batty J. Use of videotapes for viewing at

home to inform choice in Down’s syndrome screening: a randomised controlled trial. Prenat Diagn 2001;21(2):146-9.

310 Cuckle H. Integrating Down’s syndrome screening. Current Opinions in Obstetrics & Gynaecology 2001;13(2):175-81.

311 Murray J, Cuckle H. Cystic Fibrosis and fragile X syndrome: the arguments for antenatal screening. Comb Chem High Throuput Screen 2001;4(3):265-272.

312 Cuckle H. Impact of improved screening efficiency on the future role of non-invasive testing. In: Fetal Cells and Fetal DNA in Maternal Blood. (Eds. S Hahn, W Holzgreve). Karger, Switzerland, 2001:pp124-

16

130. 313 Cuckle H, Murray J. Antenatal screening for neurologic disorders. In: Fetal and Neonatal Neurology and

Neurosurgery. (Eds. MI Levene, FA Chervenak, M Whittle). Churchill Livingstone, London, UK. 2001:pp267-73.

314 Cuckle H. Time for total shift to first-trimester screening for Down’s syndrome. Lancet 2001;358:1658-9. 315 Cuckle H. Extending antenatal screening in the UK to include common monogenic disorders. Community

Genet 2001;4:84-86. 316 Arbuzova S, Cuckle H, Mueller R, Sehmi I. Familial Down syndrome: evidence supporting cytoplasmic

inheritance. Clin Genet 2001;60:456-462. 317 Khan NR, Saeed M, Cuckle HS. Maternal serum marker levels in consanguineous couples. Prenat Diagn

2001;21:1177-79. 318 Cuckle H. Dr Lippman’s commentary. Community Genet 2001;4:173. 319 Cuckle HS, Sehmi IK, Jones RG. Correlation between maternal serum PAPP-A and inhibin. Prenat Diagn

2002;22(2):161-162. 320 Cuckle HS. Absence of nasal bone and detection of trisomy 21. Lancet 2002;359(9314):1345. 321 Cuckle HS. Growing complexity in the choice of Down’s syndrome screening policy. Ultrasound Obstet

Gynecol 2002;19(4):323-326. 322 Cuckle H, Arbuzova S. The efficiency and clinical practicality of multi-modality screening strategies. In:

Early prenatal diagnosis, fetal cells and DNA in the mother: Proceedings of the 12th Fetal Cell Workshop. (Eds. M Macek, D Bianchi, H Cuckle). Charles University Press; Prague 2002: pp387-397.

323 Arbuzova S, Hutchin T, Cuckle H. Mitochondrial dysfunction and Down's syndrome. Bioessays 2002; 24(8):681-684.

324 Rozenberg P, Malagrida L, Cuckle H, Durand-Zaleski I, Nisand I, Audibert F, Benattar C, Tribalat S, Cartron M, Lemarie P, Stoessel J, Capolagui P, Jansé-Marec J, Barbier D, Allouch C, Perdu M, Roberto A, Lahna Z, Giudicelli Y, Ville Y. Down’s syndrome screening with nuchal translucency at 12+0-14+0 weeks and maternal serum markers at 14+1-17+0 weeks: a prospective study. Hum Reprod 2002;17(4):1093-1098.

325 Spencer K, Cuckle H. Screening for chromosomal anomalies in the first trimester: Does repeat maternal serum screening improve detection rates? Prenat Diagn 2002;22(10):903-906.

326 Rahim RR, Cuckle HS, Sehmi IK, Jones RG. Ultrasound dating policy in maternal serum screening for Down’s syndrome. Prenat Diagn 2002;22(13):1181-1184.

327 Cuckle HS. Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study. J Pediatr 2002 May;140(5):632-3.

328 Cuckle H. Potential biases in Down syndrome birth prevalence estimation. J Med Screen 2002;9:192. 329 Barkai G, Arbuzova A, Berkenstadt M, Heifetz S, Cuckle H. Frequency of Down's syndrome and neural-

tube defects in the same family. Lancet 2003;361(9366):1331-1335. 330 Cuckle H, Arbuzova S, Spencer K, Crossley J, Barkai G, Krantz D, Muller F, Nikolenko M, Aitken D,

Macri J, Hallahan T, Buchanan PD. Frequency and clinical consequences of extremely high maternal serum PAPP-A levels. Prenat Diagn 2003;23:385-88.

331 Logghe H, Cuckle H, Sehmi I. Centre-specific ultrasound nuchal translucency medians needed for Down’s syndrome screening. Prenat Diagn 2003;23:389-92.

332 Ferriman E, Cuckle H. Case report: clinical utility of ultrasound nasal bone determination in the prenatal diagnosis of Down syndrome. Prenat Diagn 2003;23:433-434.

333 Muller F, Benattar C, Audibert F, Roussel N, Dreux S, Cuckle H. First-trimester screening for Down syndrome in France combining fetal nuchal translucency measurement and biochemical markers. Prenat Diagn 2003;23(10):833-6.

334 Cuckle H. Principles of screening. The Obstet & Gynaecol 2004;6(1):21-25 335 Cuckle, H. Updated modelling parameters for Down syndrome screening. Balkan J Med Genet

2003;6(2&3)Supp:101-7 336 Cuckle H, Arbuzova S. Multianalyte Maternal Serum Screening for Chromosomal Defects. In: Genetic

Disorders and the Fetus: Diagnosis, Prevention and Treatment - 5th edition. (Ed Aubrey Milunsky), Johns Hopkins University Press Baltimore; 2004: pp795-835.

337 Rozenberg P, Malagrida L, Cuckle H, Giudicelli Y, Ville Y. Down’s syndrome screening with nuchal translucency at 12+0-14+0 weeks and maternal serum markers at 14+1-17+0 weeks: a prospective study. In: Focus on Down Syndrome Research. (Ed Jeffrey A Malard), Nova Medical Books USA; 2004: pp1-9.

17

338 Wright D, Bradbury I, Benn P, Cuckle H, Ritchie K. Contingent screening for Down's syndrome is an efficient alternative to non-disclosure sequential screening. Prenat Diagn 2004; 24(10): 762-766.

339 Cuckle H, Aitken D, Goodburn S, Senior B, Spencer K, Standing S. Age-standardisation for monitoring performance in Down’s syndrome screening programmes. Prenat Diagn 2004; 24(11): 851-856.

340 Green JM, Hewison J, Bekker HL, Bryant LD, Cuckle HS. Psychosocial aspects of genetic screening of pregnant women and newborns: a systematic review. Health Technol Assessment 2004; 8(33): 1-109.

341 Cuckle H, Spencer K, Nicolaides KH. Down’s syndrome screening marker levels in women with a previous aneuploidy pregnancy. Prenat Diagn 2005; 25(1): 47-50.

342 Cuckle H. Advanced maternal age is no longer so advanced. Isr Medical Assoc J 2005; 7(2): 111-112. 343 Moss S, Waller M, Anderson TJ, Cuckle H, for the Trial Management Group. Randomised controlled trial

of mammographic screening in women from age 40: predicted mortality based on surrogate outcome measures. Br J Cancer 2005;92(5):955-60.

344 Macek M, Hajek P, Cuckle H, Houbova B, Vilimova S, Potuznikova P, Simandlova M, Havlovicova M, Vlk R, Spalova I, Kulovany E, Diblik J, Hladikova M. PAPP-A/proMBP complex in prenatal screening of severe fetal disorders and postnatal detection of acute coronary disease. In: Recent Advances in Prenatal Genetic Diagnosis: Proceedings of the 12th International Congress on Prenatal Diagnosis and Therapy (Eds Z Papp, C Rodeck). Medimond; Bologna, Italy 2004: 127-131.

345 Wright D, Bradbury I, Benn P, Cuckle H, Ritchie K. Which contingent sequential screening protocol? Prenat Diagn 2005;25(6):520-521; and 25(12):1169-1170.

346 Papageorghiou AT, Yu CK, Erasmus IE, Cuckle H, Nicolaides KH. Assessment of risk for the development of pre-eclampsia by maternal characteristics and uterine artery Doppler. Br J Obstet Gynaecol 2005;112(6):703-709.

347 Benn P, Wright D, Cuckle H. Practical strategies in contingent sequential screening for Down's syndrome. Prenat Diagn. 2005;25(8):645-652.

348 Cuckle H, Benn P, Wright D. Down syndrome screening in the first and/or second trimester: model predicted performance using meta-analysis parameters. Seminars Perinatology. 2005;29:252-257.

349 Berkenstadt M, Weiss B, Cuckle H, De Castro M, Guitta E, Barkai G. Chromosomal abnormalities and birth defects among couples with colchicine treated familial Mediterranean fever. Am J Obstet Gynecol. 2005;193(4):1513-1516.

350 Maymon R, Levinsohn-Tavor O, Cuckle H, Tovbin E, Dreazen E, Weiner YM, Herman A. Fetal prenasal thickness combined with nasal bone length: a new method of Down's syndrome screening. Prenat Diagn. 2005;25(10):906-11.

351 Borrell A, Gonce A, Martinez JM, Borobio V, Fortuny A, Coll O, Cuckle H. First trimester screening for Down’s syndrome with ductus venosus in Doppler studies in addition to nuchal translucency and serum markers. Prenat Diagn. 2005;25(10):901-5.

352 Cuckle H. Primary prevention of Down’s syndrome. Int J Med Sci. 2005;2(3):93-9. 353 Maymon R, Cuckle H, Jones R, Reish O, Herman A. Predicting the result of additional second trimester

markers from a woman’s first trimester marker profile: a new concept in Down's syndrome screening. Prenat Diagn. 2005;25(12): 1102-1106.

354 Nicolaides KH, Bindra R, Turan OM, Chefetz I, Sammar M, Meiri H, Tal J, Cuckle HS. A Novel Screening of Early Pre-eclampsia in the First Trimester combining PP-13 and Doppler Ultrasound. Ultrasound Obstet Gynecol. 2006; 27(1):13-17.

355 Cuckle H. Sub-optimal Down's syndrome screening test interpretation. Ultrasound Obstet Gynecol. 2006; 27(1):6-8.

356 Maymon R, Ushakov F, Waisman D, Cuckle H, Tovbin E, Herman A. A model for second trimester Down's syndrome sonographic screening based on facial landmarks and digit length measurement. Ultrasound Obstet Gynecol. 2006;27:290-295.

357 Berkowitz RL, Cuckle HS, Wapner R, D’Alton ME. Aneuploidy Screening – What Test Should I Use? Obstet Gynecol. 2006;107(3):715-718.

358 Arbuzova S, Cuckle H. Pathogenesis and etiology of Down’s syndrome in relation to oxidative stress. In: Oxidative Stress, Disease and Cancer (Ed. Keshav K Singh). Imperial College Press; London, UK 2006: 557-576.

359 Cuckle H. Maternal serum screening for aneuploidy and neural tube defects Down syndrome screening review. In: Preventative Genetics (Ed. Sharad Gogate). Jaypee Brothers; New Delhi, India 2006: pp101-118.

18

360 Cuckle H, Arbuzova S. Epidemiology of aneuploidy. In: Prenatal diagnosis (Ed. Mark I Evans, Mark P Johnson, Yuval Yaron, Arie Drugan). McGraw-Hill; New York, USA 2006: pp19-32.

361 Wright D, Bradbury I, Cuckle H, Gardosi J, Tonks A, Standing S, Benn P. Three-Stage Contingent Screening for Down Syndrome. Prenat Diagn. 2006;26(6):528-534.

362 Maymon R, Cuckle H, Herman A. Maternal serum inhibin levels in twin and singleton pregnancies conceived by assisted reproduction. Hum Reprod. 2006;21(5):1305-1308.

363 Laigaard J, Cuckle H, Wewer UM, Christiansen M. Maternal serum ADAM12 levels in Down’s and Edwards’ syndrome pregnancies at 9-12 weeks gestation. Prenat Diagn. 2006;26(8):689-691.

364 Wright D, Bradbury I, Benn P, Nix B, Spencer K, Cuckle H. CT Ratios: Parameter estimates are inconsistent with SURUSS publications? Prenat Diagn. 2006;26(10):991-992.

365 Wright D, Bradbury I, Cuckle H, Gardosi J, Tonks A, Standing S, Benn P. A matter of opinion or evidence! Prenat Diagn. 2006;26(12):1184.

366 Rozenberg P, Bussières L, Chevret S, Bernard JP, Malagrida L, Cuckle H, Chabry C, Durand-Zaleski I, Bidat L, Lacroix I, Moulis M, Roger M, Jacquemot MC, Bault JP, Boukobza P, Boccara P, Vialat F, Giudicelli Y, Ville Y. Screening for Down syndrome using first-trimester combined screening followed by second ultrasound examination in an unselected population. Am J Obstet Gynecol. 2006;195(5):1379-1387.

367 Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L, for the Trial Management Group. Randomised controlled trial of mammographic screening from age 40: breast cancer mortality at 10 years follow-up. Lancet 2006;368:2053-2060.

368 Falik-Zaccai T, Golan N, Cuckle H. Prenatal diagnosis for chromosomal abnormality: time to change the Israeli policy. Harefuah 2006;145(12):916-922, 940. Hebrew.

369 Seifer DB, MacLaughlin DT, Cuckle HS. Serum müllerian-inhibiting substance in Down syndrome pregnancies. Hum Reprod. 2007;22(4):1017-10209.

370 Gross S, Cuckle H. Prenatal and Fetal Diagnosis - An introduction. Am J Med Genet C Semin Med Genet. 2007;145(1):1-4.

371 Hewison J, Green JM, Ahmed A, Cuckle HS, Hirst J, Hucknall C, Thornton JG. Attitudes to prenatal testing and termination of pregnancy for fetal abnormality: a comparison of white and Pakistani women in the UK. Prenat Diagn. 2007;27(5):419-430.

372 Rozenberg P, Bussières L, Chevret S, Bernard JP, Malagrida L, Cuckle H, Chabry C, Durand-Zaleski I, Bidat L, Lacroix I, Moulis M, Roger M, Jacquemot MC, Bault JP, Boukobza P, Boccara P, Vialat F, Giudicelli Y, Ville Y. Screening for Down syndrome using first-trimester combined screening followed by second ultrasound examination in an unselected population. Gynecol Obstet Fertil. 2007;35(4):303-311. French.

373 Maymon R, Levinsohn-Tavor O, Cuckle H, Tovbin Y, Dreazen E, Wiener Y, Herman A, Correlation between nasal bone length and nuchal translucency thickness. Prenat Diagn. 2007;27(4):387.

374 Cuckle H. Should CVS or amniocentesis be performed in RPL without screening? In: Recurrent Pregnancy Loss: Causes, Controversies and Treatment (Ed. Howard JA Carp). Informa Healthcare; London, UK 2007: pp55-57. 35.e1-7.

375 Chafetz I, Kuhnreich I, Sammar M, Tal Y, Gibor Y, Meiri H, Cuckle H, Wolf M. First trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol. 2007; 197: 35.e1-7

376 Breathnach FM, Malone FD, Lambert-Messerlian G, Cuckle HS, Porter TF, Nyberg DA, Comstock CH, Saade GR, Berkowitz RL, Klugman S, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Tripp T, Bianchi DW, D'Alton ME; First and Second Trimester Evaluation of Risk (FASTER) Research Consortium. First- and second-trimester screening: detection of aneuploidies other than Down syndrome. Obstet Gynecol. 2007;110(3):651-7.

377 Berkenstadt M, Ries-Levavi L, Cuckle H, Peleg L, Barkai G. Preconceptional and prenatal screening for fragile X syndrome: Experience with 40000 tests. Prenat Diagn. 2007;27(11):991-994.

378 Maymon R, Levinsohn-Tavor O, Cuckle H, Tovbin Y, Dreazen E, Wiener Y, Herman A. Correlation between nasal bone length and nuchal translucency thickness. Prenat Diagn. 2007;27(4):387.

379 Borrell A, Mercade I, Casals E, Borobio V, Seres A, Soler A, Fortuny A, Cuckle H. Combining fetal nuchal fold thickness with second trimester biochemistry to screen for trisomy 21. Ultrasound Obstet Gynecol. 2007;30:941-945.

380 Cuckle H, Arbuzova S. Down syndrome: maternal age and inheritance. In: Fifty years of human genetics: a Festschrift and liber amicorum to celebrate the life and work of George Robert Fraser (Eds. Oliver Mayo, Carolyn Leach). Wakefield Press; Kent Town, Australia 2007: pp376-384.

19

381 Evans MI, Cuckle HS. Biochemical Screening for Aneuploidy. Expert Reviews of Obstet Gynecol 2007;2:765-774.

382 Jones R, Cuckle H. Impact of analytical performance on outcomes. In: Evidence-Based Laboratory Medicine; Principles, Practice, and Outcomes, Second Edition, (eds. CP Price & RH Christenson); AACC Press, Washington DC, USA; 2007.

383 Cuckle HS, Malone FD, Wright D, Porter TF, Nyberg DA, Comstock CH, Saade GR, Berkowitz RL, Ferreira JC, Dugoff L, Craigo SD, Timor IE, Carr SR, Wolfe HM, D'Alton MA for the FaSTER Research Consortium. Contingent screening for Down syndrome – results from the FaSTER trial. Prenat Diagn. 2008;28:89-94.

384 Cuckle HS, Malone FD, Wright D, Porter TF, Nyberg DA, Comstock CH, Saade GR, Berkowitz RL, Ferreira JC, Dugoff L, Craigo SD, Timor IE, Carr SR, Wolfe HM, D'Alton MA for the FaSTER Research Consortium. Contingent screening for Down syndrome. Prenat Diagn. 2008;28:782.

385 Ahmed S, Hewison J, Green JM, Cuckle HS, Hirst J, Thornton JG. Decisions about testing and termination of pregnancy for different fetal conditions: a qualitative study of European White and Pakistani mothers of affected children. J Genet Couns. 2008;17(6):560-572.

386 Donalson K, Turner S, Wastell H, Cuckle H. Second trimester maternal serum ADAM12 levels in Down's syndrome pregnancies. Prenat Diagn. 2008;28(10):904-907.

387 Dugoff L, Cuckle HS, Hobbins JC, Malone FD, Belfort MA, Nyberg DA, Comstock CH, Saade GR, Eddleman KA, Dar P, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D'Alton ME; FaSTER Trial Research Consortium. Prediction of patient-specific risk for fetal loss using maternal characteristics and first- and second-trimester maternal serum Down syndrome markers. Am J Obstet Gynecol. 2008;199(3):290.e1-6.

388 Romero R, Kusanovic JP, Than NG, Erez O, Gotsch F, Espinoza J, Edwin S, Chefetz I, Gomez R, Nien JK, Sammar M, Pineles B, Hassan SS, Meiri H, Tal Y, Kuhnreich I, Papp Z, Cuckle HS. First-trimester maternal serum PP13 in the risk assessment for preeclampsia. Am J Obstet Gynecol. 2008;199(2):122.e1-122.e11.

389 Maymon R, Zimerman AL, Weinraub Z, Herman A, Cuckle H. Correlation between nuchal translucency and nuchal skin-fold measurements in Down syndrome and unaffected fetuses. Ultrasound Obstet Gynecol. 2008;32(4):501-505.

390 Wortelboer EJ, Linskens IH, Koster MP, Stoutenbeek P, Cuckle H, Blankenstein MA, Visser GH, van Vugt JM, Schielen PC. ADAM12s as a first-trimester screening marker of trisomy. Prenat Diagn. 2009;29:866-869.

391 Koster MPH, Wortelboer EJ, Cuckle HS, Stoutenbeek P, Visser GHA, Schielen PCJI. Placental protein 13 as a first-trimester screening marker for aneuploidy. Prenat Diagn. 2009;29(13):1237-1241

392 Maymon R, Moskovitch M, Levinsohn-Tavor O, Weinraub Z, Herman A, Cuckle H. Bed side estimation of Down's syndrome risk from second trimester ultrasound prenasal thickness. Ultrasound in Obstetrics and Gynecology. 2009;34(6):629-633.

393 Aagaard-Tillery KM, Malone FD, Nyberg DA, Porter TF, Cuckle HS, Fuchs K, Sullivan L, Comstock CH, Saade GR, Eddleman K, Gross S, Dugoff L, Craigo SD, Timor IE, Carr SR, Wolfe HM, Bianchi DW and D'Alton ME for the FaSTER Research Consortium. Role of second trimester genetic sonography following Down syndrome screening. Obstet Gynecol 2009;114(6):1189-96.

394 Sharony R, Itzhaky D, Amiel A, Fejgin M, Cuckle H. Maternal serum Triple marker levels in immigrants to Israel from Ethiopia. Fetal Therapy and Diagnosis. 2009;26(4):200-202.

395 Cuckle HS, Benn PA. Multianalyte Maternal Serum Screening for Chromosomal Defects. In: Genetic Disorders and the Fetus: Diagnosis, Prevention and Treatment - 6th edition. (Ed A Milunsky & JM Milunsky), Wiley-Blackwell Chichester, 2010; pp 771-818.

396 Kingston N, Thomas I, Johns L, Moss S, Cuckle H, Evans A, Bobrow L, Kutt E, Record C, Thomas B. Assessing the amount of unscheduled screening ("contamination") in the control arm of the UK "Age" Trial. Cancer Epidemiol Biomarkers Prev. 2010;19(4):1132-6.

397 Johns LE, Moss SM, Cuckle H, Evans A, Kutt E, Record C, Thomas BA. Randomised controlled trial of mammographic screening from age 40 (‘Age’ trial): patterns of screening attendance. J Med Screen. 2010;17(1):37-43.

398 Cuckle H. Monitoring Quality Control of Nuchal translucency. Clin Lab Med 2010;30:593-604. 399 Wright D, Bradbury I, Malone F, Summers A, Huang T, Ball S, Baker A, Nix B, Aitken D, Crossley J,

Cuckle H, Spencer K. Cross Trimester Repeated Measures Testing for Down’s Syndrome Screening.

20

Health Technology Assessment 2010;14(33):1-80. 400 Cuckle H, Maymon R. Down’s syndrome risk calculation for a twin fetus taking account of the nuchal

translucency in the co-twin. Prenat Diagn. 2010;30(9):827-33. 401 Wortelboer EJ, Koster MPH, Cuckle H, Stoutenbeek P, Schielen PCJI, Visser GHA. First-trimester PP13

and PlGF: sensitive markers for identification of patients destined to develop early-onset preeclampsia. Brit J Obstet Gynaecol. 2010;117(11):1384-9.

402 Miguelez J, Maymon R, Cuckle H, Zugaib M, Bunduki V, Herman A. Model predicted performance of second trimester Down syndrome screening with ultrasound prenasal thickness. J Ultrasound Med. 2010;29(12):1741-7.

403 Johns L, Moss S, Cuckle H, Bobrow L, Evans A, Kutt E, Record C, Thomas B. False-positive results in the UK Age trial. Cancer Epidemiology, Biomarkers & Prevention 2010;19(11):2758-64.

404 Ashoor G, Maiz N, Cuckle H, Jawdat F, Nicolaides KH. Maternal thyroid function at 11-13 weeks of gestation in fetal trisomies 21 and 18. Prenat Diagn. 2011;31(1):33-7.

405 Cuckle HS. Screening for pre-eclampsia – lessons from aneuploidy screening. Placenta 2011;32:S42-8. 406 Cetin I, Huppertz B, Burton G, Cuckle H, Gonen R, Lapaire O, Mandia L, Nicolaides K, Redman C,

Soothill P, Spencer K, Thilaganathan B, Williams D, Meiri H. What do we require from markers, risk assessment and model systems to tailor preventive strategies? Placenta 2011;32:S4-16.

407 Maymon R, Rozen H, Baruchin O, Herman A, Cuckle H. Model predicted Down’s syndrome detection rates for nuchal translucency screening in twin pregnancies. Prenat Diagn. 2011; 31(5):426-9.

408 Benn P, Borell A, Crossley J, Cuckle H, Dugoff L, Gross S, Johnson J, Maymon R, Odibo A, Schielen P, Spencer K, Wright D, Yaron Y. Aneuploidy Screening: a Position Statement from a Committee on Behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn. 2011; 31: 519–522.

409 Evans MI, Cuckle HS. Performance adjusted risks (PAR): a method to improve the quality of algorithm performance while allowing all to play. Prenat Diagn. 2011; 31(8):797-801.

410 Krantz D, Hallahan T, Ravens R, He K, Cuckle H, Sherwin J, Carmichael J. First trimester Down syndrome screening with dried blood spots on a dual analyte free beta-hCG and PAPP-A immuno-fluorometric assay. Prenat Diagn. 2011; 31(9):869-874.

411 Cuckle H. Care of the fetus: Screening. In: Oxford Desk Reference: Obstetrics and Gynaecology (Ed S Arulkumaran, L Regan, A Papageorghiou and A Monga). Oxford University Press, Oxford, UK 2011: pp168-171.

412 Benn P, Borrell A, Cuckle H, Dugoff L, Gross S, Johnson J, Maymon R, Odibo A, Schielen P, Spencer K, Wright D, Yaron Y. Prenatal Detection of Down Syndrome using Massively Parallel Sequencing (MPS): a rapid response statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn. 2012;32(1):1-2.

413 Benn P, Cuckle H, Pergament E. NIPD for Down syndrome – the paradigm will shift but slowly. Ultrasound Obstet Gynecol. 2012;39(2):127-30.

414 Cuckle H, Moskovitch M, VakninZ, Levental S, Rosen H, Maymon R. Nuchal translucency screening in triplets: Down’s syndrome risk calculation taking account of between-fetus correlations. Prenat Diagn. 2012;39(3);214-9.

415 Evans MI, Wright DA, Pergament E, Cuckle HS, Nicolaides KH. Digital PCR for noninvasive detection of aneuploidy: power analysis equations for feasibility. Fetal Diagn Ther 2012; 31(4):244-7.

416 Miron J-P, Cuckle H, Miron P. Prenasal thickness in first-trimester screening for Down syndrome. Prenat Diagn. 2012;32(7):695-7.

417 Benn P, Cuckle H, Pergament E. Genome-wide fetal aneuploidy detection by maternal plasma DNA sequencing. Obstet Gynecol. 2012;119(6):1270.

418 Benn P, Cuckle H, Pergament E. Non-invasive prenatal diagnosis for Down syndrome: no paradigm shift, just better testing. . .and it is already here! Ultrasound Obstet Gynecol. 2012;40:484-8.

419 Bernard JP, Cuckle HS, Stirnemann JJ, Salomon LJ, Ville Y. Screening for fetal spina bifida by ultrasound examination in the first trimester of pregnancy using fetal biparietal diameter. Am J Obstet Gynecol. 2012 207(4):306.e1-5.

420 Cuckle H, von Dadelszen P, Ghidini, A. Current controversies in prenatal diagnosis 4: pregnancy complications due to placental vascular disease (pre-eclampsia, FGR): are we ready for prevention? Prenat Diagn. 2013;33(1):17-20.

421 Yaron Y, Musci T, Cuckle H. Current controversies in prenatal diagnosis 1: Screening for fragile X syndrome. Prenat Diagn. 2013;33(1):6-8.

21

422 Rosenfeld JA, Ballif BC, Coe BP, Eichler EE, Cuckle H, Shaffer LG. Estimates of penetrance for recurrent pathogenic copy-number variations. Genet Med. 2013;

423 Borrell A, Grande M, Bennasar M, Borobio V, Jimenez JM, Stergiotou I, Cuckle H. First trimester detection of cardiac defects with the use of the ductus venosus blood flow. Ultrasound Obstet Gynecol. 2013;42(1):51-7.

424 Cuckle H, Maymon R. Role of second trimester ultrasound in screening for Down’s syndrome. Ultrasound Obstet Gynecol. 2013;41:241-4.

425 Donalson K, Turner S, Morrison L, Liitti P, Nilsson C, Cuckle H. Maternal serum placental growth factor and α-fetoprotein testing in first trimester screening for Down’s syndrome. Prenat Diagn. 2013;33:1-5.

426 Rosenfeld JA, Coe BP, Eichler EE, Cuckle H, Shaffer LG. Response to Benn. Genet Med. 2013;15(4):317-8.

427 Cuckle H, Benn P, Pergament E. Maternal cfDNA screening for Down’s syndrome – a cost sensitivity analysis. Prenat Diagn. 2013;33(7):636-42.

428 Benn P, Cuckle H, Pergament E. Non-invasive prenatal diagnosis for aneuploidy – current status and future prospects. Ultrasound Obstet Gynecol. 2013; 42: 15–33.

429 Svirsky R, Meiri H, Herzog A, Kivity V, Cuckle HS, Maymon R. First trimester maternal serum placental protein 13 levels in singleton versus twin pregnancies with and without severe pre-eclampsia. J Perinat Med. 2013; 41(5): 561-6.

430 Benn P, Borell A, Chiu R, Cuckle H, Dugoff L, Faas B, Gross S, Johnson J, Maymon R, Norton M, Odibo A, Schielen P, Spencer K, Huang T, Wright D, Yaron Y. Position Statement from the Aneuploidy Screening Committee on Behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn. 2013;33:622–629

431 Bernard J-P, Cuckle HS, Bernard M, Brochet C, Salomon LJ, Ville Y. Combined screening for open spina bifida at 11-14 weeks using fetal biparietal diameter and maternal serum markers. Am J Obstet Gynecol. 2013; 209(3): 223.e1-5.

432 Johnson J, Pastuck M, Metcalf A, Nilsson C, Connors G, Krause R, Wilson D, Cuckle H. New approaches to first trimester Down’s syndrome screening using additional serum markers and cell free DNA. Prenat Diagn. 2013; 33: 1044-1049.

433 Ben-Ami I, Maymon R, Svirsky R, Cuckle H, Jauniaux E. Down's syndrome screening in assisted conception twins: an iatrogenic medical challenge. Obstet & Gynecol Survey. 2013;68(11):764-73.

434 Cuckle H. Re: Repeat measurements of nuchal translucency at 11–14 weeks of gestation: when do we need them? L.J. Salomon, R. Porcher, D. Socolov, H. Lamrani and Y. Ville. Ultrasound Obstet Gynecol 2013; 42: 629-633. Ultrasound Obstet Gynecol 2013;42(6):613.

435 Benn P, Borell A, Chiu R, Cuckle H, Dugoff L, Faas B, Gross S, Johnson J, Maymon R, Norton M, Odibo A, Schielen P, Spencer K, Huang T, Wright D, Yaron Y. Response to “On gestational weeks and maths”. Prenat Diagn. 2013;33(12):1218-9.

436 Bernard J-P, Cuckle HS, Bernard M, Brochet C, Salomon LJ, Ville Y. The role of maternal serum AFP in screening for open spina bifida at 11-14 weeks. Reply. Am J Obstet Gynecol. 2014;210(2):172-3.

437 Cuckle H, Benn P, Pergament E. Clinical Utility and Cost of Non-Invasive Prenatal Testing. J Matern Fetal Neonatal Med. 2014;27(3):320-1.

438 D'Alton ME, Fuchs KM, Abuhammad A, Benacerraf B, Berkowitz R, Cuckle H, Depp R, Goldberg J, OKeeffe D, Platt LD, Spitz JL, Toland G, Wapner R; Nuchal Translucency Quality Review Program. Implementation of a national nuchal translucency education and quality monitoring program. Obstet Gynecol. 2014;123(1):149-54.

439 Maymon R, Cuckle H, Svirsky R, Sheena L, Melcer Y, Rozen H, Ben-Ami I. Nuchal translucency in twins according to assisted conception and chorionicity. Ultrasound Obstet Gynecol. 2014;44(1):38-43.

440 Pergament E, Cuckle H, Zimmermann B, Banjevic M, Hill M, Sigurjonsson S, Ryan A, Dodd M, Lacroute P, Hall M, McAdoo S, Savage M, Demko Z, Siddiqui A, Rabinowitz M. Single-nucleotide polymorphism-based non-invasive prenatal testing in a high- and low-risk cohort. Obstet Gynecol. 2014;124(2 Pt 1):210-8.

441 Krantz DA, Cuckle HS. Extrapolation of Maternal Weight in Sequential Aneuploidy Screening. Prenat Diagn. 2014;34(8):753-8.

442 Benn P, Cuckle H. Theoretical performance of non-invasive prenatal testing for chromosome imbalances using counting of cell-free DNA fragments in maternal plasma. Prenat Diagn. 2014;34(8):778-83.

443 Cuckle H. Steering the course between optimal policies and practical constraints. J Fet Med. 2014;1:3-5.

22

444 Svirsky R, Yagel S, Ben-Ami I, Cuckle H, Maymon R. First trimester markers of pre-eclampsia in twins: mean arterial pressure and uterine artery Doppler pulsatility index. Prenat Diagn. 2014;34(10);956-60.

445 Davis C, Cuckle H, Yaron Y. Screening for Down syndrome – incidental diagnosis of other aneuploidies. Prenat Diagn. 2014;34(11):1044-8.

446 Sonek JD, Cuckle HS. What will be the role of first trimester-ultrasound if cell-free DNA screening for aneuploidy becomes routine? Ultrasound Obstet Gynecol. 2014;44:621-30.

Available online: Cuckle H, Platt L, Thornburg L, Bromley B, Abuhamad A, Benacerraf B, Copel JA, Depp R, D'Alton M,

Goldberg J, Okeeffe D, Spitz J, Toland G, Wapner R; the Nuchal Translucency Education and Quality Review Program of the Perinatal Quality Foundation. First One and Half Million Results. Ultrasound Obstet Gynecol.

In press: Cuckle H. Prenatal screening using maternal markers. J Clin Med. Cuckle H. Should CVS or amniocentesis be performed in RPL without screening? In: Recurrent Pregnancy

Loss: Causes, Controversies and Treatment (Ed. Howard JA Carp). Second edition. Cuckle H, Benn P, Mejides A. Maternal screening for chromosomal abnormalities. Cuckle HS, Pergament E, Benn P. NIPT for aneuploidy as a clinical service. Clin Biochem. Cuckle HS, Pergament E. Multianalyte Maternal Serum Screening for Chromosomal Abnormalities and Neural

Tube Defects. In: Genetic Disorders and the Fetus: Diagnosis, Prevention and Treatment - 7th edition. (Ed A Milunsky & JM Milunsky).

Norton ME, Jacobsson B, Swami G, Laurent L, Pereira L, Cuckle H, Spitz J, Brar H, Ranzini A, Tomlinson M, Hollemon D, Musci TJ, Wapner RJ. Non-invasive EXamination of Trisomy using Directed Cell Free DNA Analysis: The NEXT Study.

Submitted: Huang T, Dennis A, Meschino WS, Rashid S, Mak-Tam E, Cuckle H. First trimester screening for Down

syndrome using nuchal translucency, maternal serum pregnancy-associated plasma protein A, free-β human chorionic gonadotrophin, placental growth factor and α-fetoprotein.

Writing or pending submission: Bérubé D, Cuckle H, Bujold E, Gagné M, Couturier B, Jacques Kadoch I. New approach in non-invasive

prenatal testing for aneuploidies in maternal plasma: droplet digital PCR system. Ginsberg GM, Zlotogora J, Cuckle H. Cost-Utility Analysis of cfDNA Screening for Down's Syndrome in

Israel. Grobman W, Pergament E, Cuckle HS. Cost-benefit analysis of NIPT in different health care systems. Maymon R, Cuckle H. History of screening in obstetrics: the good the bad and the ugly. Seminars in

Perinatology Yagel S, Benacerraf B, Cuckle H, Kagan K, Van den Veyver I, Wapner R. Non-Invasive Prenatal Testing

(NIPT) and Fetal Ultrasound Screening. J Ultrasound Med.